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ABSTRACT 
 
   The present investigations focus on the evaluation of the organotypic culture of rat epidermal 
keratinocytes (ROC) as a skin permeation and irritation model. The outermost layer of the skin, 
the stratum corneum, is responsible for skin impermeability towards external substances. The 
intercellular lipid matrix of the stratum corneum serves as the principal penetration route for 
most substances. It is also the target for permeation enhancer action, a commonly used approach 
to increase transdermal drug delivery. In addition, in topical administration, skin irritation 
reactions are strongly related to the function of the skin barrier. 
   Analysis of the lipids in ROC stratum corneum revealed the presence of the major skin lipid 
classes, ceramides, cholesterol and free fatty acids, in similar proportions as was found in 
human skin, which highly supports similarity of the lipoidal barrier in the membranes. 
However, the permeation barrier of ROC to drug molecules has previously been reported to be 
slightly more leaky than human skin. This difference could be now explained by the analysed 
differences in molecular structure and composition of ceramides, as well as the lower amount of 
covalently bound ceramides in ROC. Also the thermal behavior of the lipids present in ROC 
stratum corneum differed from that in human skin and this may account for some structural 
differences in the lipid matrix. 
   In the present study, a variety of methods for testing the chemical induced skin irritation with 
ROC were introduced. Cell membrane integrity (LDH leakage), pro-inflammatory effect (IL-1α 
release) and morphological perturbation of culture were used as the end-points of irritation. The 
results were successfully correlated to in vivo data, and the validity of the ROC model as a good 
predictor of skin irritation was proved. ROC was also demonstrated to classify chemical 
irritation more closely than commercial skin models. 
   Permeation enhancers alter the lipid matrix of stratum corneum and, subsequently, decrease 
the barrier integrity. This is important for drug delivery and may have major therapeutic 
implications. The tested enhancers were found to increase the permeation of a lipophilic model 
drug, corticosterone, to the same extent in both membranes, pointing to similarities in the lipid 
pathways. In contrast, significantly higher permeability of ROC for the hydrophilic model drug, 
sucrose, indicative of a greater number of polar pathways in the model. This is probably related 
to the less ordered lipid lamellae in ROC, which is supported by the results from thermal 
analysis of ROC stratum corneum lipids. 
   There is a need for alternative cell models which could reduce, refine and replace animal tests 
in drug development and chemical testing. Reconstructed skin models could be the optimal 
choice but the major limitation in general is inadequate stratum corneum barrier compared to 
human skin. The ROC was shown to produce a barrier function which was very similar to 
human skin. It was also shown to be a good model for predicting skin irritation by chemical 
exposure and it can be used, with some limitations, in evaluating the effect of permeation 
enhancers. 
 
National Library of Medicine Classification: WR 100, WR 102, QU 300, QU 375, QV 38 
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biological; toxicity tests 
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1 INTRODUCTION 
 
   Skin diseases are frequently medicated by topical formulations. They are more 
convenient than oral formulations, because a smaller dose of drug is required for the 
local effect and the systemic side-effects can be minimized. In addition to the localised 
dermal treatments, the drugs can delivered across the skin for the treatment of systemic 
diseases. Transdermal drug delivery can permit sustained drug release resultig in more 
stable plasma levels compared to that which can be achieved after oral drug 
administration. The variability in per oral drug delivery is caused by the site-dependent 
absorption, drug degradation, and presystemic metabolism.  Drug administration via the 
skin is hampered by the poor permeability of the skin and by local adverse drug effects. 
   The skin is the outermost organ of the body that provides a physical and metabolic 
barrier for entry of harmful substances (microorganisms and chemicals) and prevents 
the loss of endogenous substances, particularly water. The low permeability of the skin 
is due to the unique structure of outermost layer of the skin, stratum corneum 
(Scheuplein and Blank 1971). Thus, dermal and transdermal drug delivery is a 
challenging task. In general, sufficiently lipophilic and small molecules are capable of 
penetrating into and through the skin to provide the required pharmacological effects 
(Potts and Guy 1992). In order to widen the spectrum of molecules which can be 
administered by dermal and transdermal delivery, the skin barrier should be overcome 
safely and reversibly. Several chemical, electrical and mechanical methods have been 
used to enhance skin permeability by evoking structural alterations in the stratum 
corneum (Barry 2001). Chemical permeation enhancers can be added to the topical 
formulations to improve drug permeation across the skin. Unfortunately, these 
compounds sometimes cause skin irritation.  
   Excised specimens of animal and human skin can be used to test topical drug 
formulations ex vivo. Novel substitutes are being developed because excised specimens 
have limited availability, variable quality, and lack of viability. Another important 
aspect is the use of the alternative cell models could reduce, refine and replace some 
animal testing. The European Union legislation for chemical testing (REACH) was 
launched in 2006. REACH requires biological testing of all chemicals that are sold or 
produced in European Union above threshold limits. Preferably the testing should be 
done without animal experiments. Thus there is a need for alternative skin models both 
in drug development and chemical testing. 
   Three-dimensional reconstructed models of skin epidermis are promising methods due 
to their morphological and biological resemblance to human skin (Ponec et al. 2002). 
Unlike excised skin samples, the cell models are viable and they can be used to study 
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biochemical responses to the treatments. Before they can receive official recognition as 
an alternative to human skin, the predictive capacity of the cell models relative to 
human skin will need to be assessed. At the moment, validated methods are available 
only for the evaluation of chemical corrosion (ECVAM 1998 and 2000). Skin cell 
models have been used for the prediction of cutaneous irritancy, percutaneous 
absorption, and metabolism in the skin (Fentem et al. 2001; Hammel et al. 2005), but 
the effects of drug permeation enhancers have not been studied with skin cell models. 
The major limitation of the skin cell models seems to be the inadequate stratum 
corneum barrier as compared to native skin.  
   Epidermal skin models are typically reconstructed from freshly separated or early 
passage human keratinocytes (Rosdy and Clauss 1990). This time-consuming process 
does not provide an identical epidermal barrier to the human skin. The continuous cell 
lines are easier to use, but the quality of those culture models is not satisfactory (Ponec 
et al. 2000a). The organotypic culture of rat epidermal keratinocytes (ROC) utilize a 
continuous keratinocyte cell line derived from newborn rat skin (REK) (Pasonen-
Seppänen et al. 2001a; Suhonen et al. 2003). ROC is able to possess rather similar 
barrier properties as human skin. In the present thesis, the composition of the stratum 
corneum lipid domain was compared to isolated human skin. In addition, the ROC 
model was evaluated in the assessment of chemical irritation. Finally, the alteration of 
the membrane barrier by the chemical permeation enhancers and topical formulation 
was investigated. 
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2 REVIEW OF LITERATURE 
   
2.1 The structure of the skin 
 
   Skin is divided structurally and functionally into three distinct layers, the outer 
epidermis, the inner dermis and subcutaneous fat tissue (Fig 1). The dermis contains 
blood vessels, lymphatics, nerve endings and appendages (sweat glands, hair follicles, 
sebaceous glands), and thus provides physiological support for epidermis. The avascular 
epidermis can be further divided into four morphologically and biochemically different 
cell layers; basal cells, spinous cells, granular cells and cornified stratum corneum. The 
epidermis constitutes a dynamic system in which the major cell type, keratinocytes, 
differentiate during the passage from the proliferating basal keratinocytes to the surface 
of the horny layer where the dead keratinocytes, referred to as corneocytes, are 
eventually discarded (Elias 1989). This process takes about 2-3 weeks. 
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Figure 1. The structure of the skin. 
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   The stratum corneum (SC) The SC is the outermost portion of epidermis and 
consists of terminally differentiated flattened and keratin filled corneocytes embedded 
in a matrix of lipid bilayers (Elias 1983; Wertz and Downing 1989). During the 
differentiation process, the viable keratinocytes secrete a variety of SC lipid precursors 
(glycosphingolipids, free sterols and phospholipids) and catabolic enzymes (β-
glucocerebroside, sphingomyelinase, phospholipase A) which are enclosed into 
vesicles, lamellar bodies, in granular cells (Fig 2) (Freinkel and Traczyk 1985). The 
cellular remodelling takes place in the upper granular cell layer, and simultaneously 
with cell terminal keratinisation, the lipid stacks and enzymes of lamellar bodies are 
released into the intercellular space in the SC (Landmann 1986; Elias et al. 1998). The 
cornified cell envelope replaces the plasma membrane in corneocytes as the endpoint of 
epidermal differentiation and cell death. In the cornified envelope, several proteins 
(keratin, loricrin, filaggrin, involucrine) are highly cross-linked by transglutaminase, 
from which involucrine is adjacent to the cell membrane (Candi et al. 2005). This 
highly water in-soluble protein envelope is embedded in the lipid envelope, where the 
long-chain ω-hydroxyceramides are covalently linked to glutamate residue of 
involucrine through an ester bond (Swartzendruber et al. 1987; Steward and Downing, 
2001). The covalently bound lipid envelope may be assumed to function as an anchor 
between the cornified protein envelope and intercellular lipids, which is crucial for the 
proper orientation of SC lipid lamellae. Furthermore, desmosomes interconnect the 
corneocytes and are also important for the SC cohesion (Madison et al. 1987). Due to its 
unique structure, SC prevents desiccation of underlying tissues and excludes the entry 
of harmful materials, such as micro-organisms and chemicals, into the body. 
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2.2 Stratum corneum lipid composition  
 
2.2.1 Methods 
 
   The biological extracts of the human SC are known to contain a variety of lipid 
species. For example, even a single class of ceramides is estimated to contain about 250 
different ceramides that combine sphingosine bases and fatty acids of different chain 
lengths (Rieger 1996). This poses major challenges to the lipid analysis methods. The 
traditional quantitative lipid analysis is based on thin layer chromatography (TLC), gas 
chromatography (GC), and high-performance liquid-chromatography (HPLC) (Christie 
2003). TLC is the method of choice for the first analysis of the lipid classes from SC 
extracts (Melnik et al. 1989). TLC and HPLC are the main methods used for lipid 
separation prior to further analysis.  These methods do not yield structural information 
about the lipids. The fatty acid profile of SC lipid classes is commonly determined by 
gas chromatography (GC), a technique that requires fatty acid methyl ester (FAME) 
derivatisation (Lampe et al. 1983). In addition to the tedious handling procedures, the 
above techniques are time-consuming and insensitive. Mass spectrometry (MS) is a 
powerful analytical tool that can supply qualitative and quantitative data. Common 
approaches in MS analysis of lipids have utilized triple- or hybrid quadrupole 
instruments and more recently soft ionization techniques, such as electrospray 
ionization (ESI), atmospheric pressure chemical ionization (APCI), atmospheric 
pressure photoionization (APPI)  and matrix-assisted laser desorption ionization 
(MALDI) (reviewed by Uphoff et al. 2008). The analysis of lipids by MS is still much 
more complicated than e.g. the analysis of proteins, and the preseparation of lipids from 
crude tissue extract is required. Relatively few practical MS applications have emerged 
so far to analysis of skin lipids, partly due to the lack of suitable standards. 
   Lipid extraction Before their analysis the SC lipids must be extracted without 
contaminants from the tissue material. Commonly used methods for collecting skin 
lipids include the skin separation, tape-stripping, and topical solvent extraction. Free 
lipids of SC can be sequentially extracted with various organic solvents followed by 
washing of the organic phase with a polar solvent to remove contaminants (Bligh and 
Dyer 1959; Folch et al. 1959). Covalently bound lipids can be removed from the tissue 
material after the extraction of free lipids by mild alkaline hydrolysis of the remaining 
tissue (Wertz et al. 1989). 
   Thin layer chromatography (TLC) Individual lipid classes of SC extract are 
separated based on their polarity on a TLC silica gel plate with different mobile solvent 
systems. There are numerous TLC techniques available for this purpose, and some of 
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them utilise two-dimensional migration to improve the separation of the lipids (Freinkel 
and Traczyk 1985; Law et al. 1995). The lipid spots can be detected by various spray 
reagents, identified by lipid standards chromatographed simultaneously alongside the 
samples, and quantitatively analysed by photodensitometry. All lipid classes of SC can 
be identified with suitable TLC technique. TLC does not provide structural information 
about the lipids, but the separated lipid spots can be further analysed by other 
techniques. 
   Mass spectrometry (MS) Mass-spectrometric methods, particularly electrospray 
ionization mass spectrometry (ESI-MS) and tandem mass spectrometry (MS/MS), have 
been successfully used in lipid analysis (Raith and Neubert 2000). The lipid extract of 
SC contains a variety of lipid species that are structurally very similar. Therefore, the 
MS is not capable of resolving them from the tissue samples.  Chromatographic 
methods (TLC, GC, LC) are typically applied for the separation of lipids prior to their 
MS analysis. The GC/MS method has been used for analysing molecular profile of 
ceramides, but it requires pre-separation of the ceramides with TLC, followed by the 
hydrolysis and derivatization of the ceramides (Wertz et al. 1985). The methylated free 
fatty acids can also be analysed with GC/MS (Norlén et al. 1998). The replacement of 
TLC based pre-separation by HPLC has enabled on-line coupling to the MS (Farwanah 
et al. 2003; Yamane 2003). These combinations allow the lipid analysis  directly from 
the crude lipid extract and also the detection of low abundance species. Unfortunately, 
the sterols, like cholesterol, are not readily ionised and therefore they cannot be 
analyzed by ESI-MS without derivatization. At present these techniques have been 
introduced for selective detection of ceramide classes directly from the SC extract 
(Farwanah et al. 2003; Yamane 2003). However, the efficient use of MS in analysis of 
skin lipids is limited by the lack of suitable standards. 
 
2.2.2 Lipid composition of human SC 
 
   The total lipid content of human  SC is about 14% of the dry mass (Swarzendruber et 
al. 1987). A unique mixture of SC lipids is formed when polar lipid precursors are 
converted into highly non-polar lipids including ceramides (30-41%), cholesterol (20-
32%) and free fatty acids (9-25%), and a small amount of cholesterol sulfate (2-5%) 
(Wertz and Downing 1989; Broad et al. 1991; Elias 1992). A trace amount of several 
other lipid classes, such as glycosylceramides, sterol esters, di-/triglycerides, squalene, 
which may in part be of sebaceous gland origin, also persists. In contrast to all other 
lipid membranes in the body, phospholipids are largely absent from the SC. However, 
the lipid composition and content of SC vary according to the part of the body (Lampe 
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1983). Currently nine classes of uniquely structured ceramides have been identified in 
human SC (Fig 3) (Ponec et al. 2003). These ceramides are composed of long-chain 
base (sphingosine, phytosphingosine or 6-OH-sphingosine), and amide-linked (non-
hydroxy or hydroxy) fatty acids which are typically >16 carbons in length. In ester-
linked ceramides, an additional ω-esterified linoleic acid residue is present. The FFAs 
found in the human SC are longer than in other biological membranes, being 
predominantly C24:0 and C26:0 (Ponec et al. 2003). Cholesterol sulfate plays an 
important role in the inhibition of enzymes which are responsible for skin desquamation 
but also reduces the amount of cholesterol that phase separate in crystalline domains 
(Bouwstra et al. 1998b; Sato et al. 1998). 
 
 
 
Figure 3. Molecular structure of human ceramides. Sphingosine (S), phytosphingosine (P), and 
6-hydroxysphingosine (H) serve as bases in ceramides containing ester-linked (EO), non-
hydroxy (N) and α–hydroxy acids (A) (Ponec et al. 2003, with permission). 
 
2.3 Stratum corneum lipid organisation  
 
2.3.1 Methods 
 
   The SC lipid organisation is considered to be very important for the skin barrier 
function and for this reason it has been investigated rather extensively. In the 1970s, 
freeze fraction electron microscopy revealed for the first time the existence of lipid 
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multilayers between the corneocytes (Breathnach et al. 1973). Later fixation of SC with 
ruthenium tetroxide which permitted transmission electron microscopy demonstrated 
that the lipid lamellae are arranged in a repeating pattern with electron translucent bands 
in a broad-narrow-broad sequence (Madison et al. 1987). Subsequently, even more 
specific biophysical method have been introduced (Table I). 
   X-ray diffraction Several biophysical methods introduced in Table I are useful in 
establishing the phase behavior of lipids in SC. However, X-ray diffraction is the only 
technique for direct structural analysis of lipid organisation in SC. The produced X-rays 
are transported across the sample and intensity of the scattered X-rays are measured. 
From analysis of the intensity and angular dependence of the diffraction pattern, spacing 
and orientation between repeating units can be determined. Small angle (between 0 and 
5˚) X-ray diffraction technique (SAXD) provides information about large structural 
units in SC, such as repeat distance of lamellar packing (Bouwstra et al. 1991). This is 
difficult with other methods. In the case of wide angle X-ray diffraction (WAXD) 
smaller structural units, such as lateral packing of lipids in lamellae, can be detected 
(Bouwstra et al. 1992). The structural order of lamellar and lateral lipid packing can be 
monitored upon heating. 
   Differential scanning calorimetry (DSC) Transformation of lateral lipid packing from 
orthorhombic (crystalline) to hexagonal (gel phase) and hexagonal to triclinic (liquid 
phase) reduces the lattice density and increases alkyl chain mobility (Bouwstra and 
Ponec 2006) (Fig 4). This kind of lipid fluidisation can also be related to an increase in 
the gauche conformer of the lipid hydrocarbon tail (Knutson et al. 1987). These phase 
transitions are induced by raising the temperature gradually, but not all lipids in SC 
undergo their phase transition simultaneously. DSC is extensively used in studying the 
phase behavior of SC, although it provides no direct information about the lipid 
organisation. DSC studies have revealed four lipid-associated thermal transitions in 
human SC at approximately 35 (T1), 55 (Tx), 65 (T2), 80 (T3) ºC (Golden et al. 1986; 
Gay et al. 1994). Combination of DSC data or thermal analysis of SC with other 
methods such as FTIR, SAXD and WAXD have provided evidence for the following 
impications of these transitions. The thermal transition T1 has been related to the solid-
to-fluid transition for a small subset of lipids or the transformation from a orthorhombic 
to a hexagonal packing of lipids in different domains within the SC (Bouwstra et al. 
1992; Kennedy et al. 1996). The transition Tx has been attributed to the loss of 
crystalline, orthorhombic lattice structure of covalently bound lipids in the cornified 
envelope (Gay et al. 1994; Silva et al. 2006), though this does not seem to occur in all 
cases. The main lipid-associated T2 transition is believed to be due to disordering of a 
lamellar lipid phase, or more precisely, to a transition from a gel phase to a liquid
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Table I. Biophysical methods for use in studing the SC of human skin. 
Method Obtained 
information 
Comments References 
Lipid domain   
Calorimetry   
 DSC, DTA Thermal lipid phase 
transitions 
 
 
Dependent on lipid composition and lipid 
arrangement. Lipid-associated transitions 
are typically observed at about 35, 55, 65 
and 80 ˚C. 
Golden et al. 1986 
Gay et al. 1994 
 
 
 
Infrared spectroscopy 
  
 FTIR,     
ATR-FTIR 
 
 
 
 
 
 
Degree of 
hydrocarbon order 
 
 
 
 
 
 
The symmetric and asymmetric CH2 
stretching modes at ~2850 and 2920 cm-1. 
Increased number of gauche comformer 
causes a shift toward the higher 
wavenumbers. Orthorhombic to hexagonal 
transition at 20-40 ºC and hexagonal to 
disorder transition at 80-90 ºC can be 
monitored. 
Mendelsohn 2006 
 
 
 
 
 
 
 
 
 
Lipid lateral packing 
 
 
 
 
 
CH2 scissoring and rocking modes at 1462, 
1473 cm-1 and 720,730 cm-1, respectively, 
indicating orthorhombic packing. Splitting 
of the frequencies will approach each other 
at the point of orthorhombic to hexagonal 
transition at ~40 ºC.  
 
X-ray diffraction   
 SAXD Lipid lamellar 
packing 
 
 
Long periodicity phase (LPP) 13.4 nm and 
short periodicity phase (SPP) 6.4 nm.  
Disordering of the lamellar phase at 65- 
75 ˚C. 
Bouwstra et al. 1991 
Schreiner et al. 2000 
 
 
 WAXD Lipid lateral packing 
 
 
 
 
Orthorhombic lateral packing. 
Orthorhombic to hexagonal transition  
at 40 ˚C and disappearance of hexagonal 
packing  at 75-95 ˚C. 
Bouwstra et al. 1992 
ED Lipid lateral packing 
as a function of 
depth 
Orthorhombic lateral packing. 
Orthorhombic to hexagonal transition at 30-
40 ˚C. 
Pilgram et al. 1999 
Bouwstra and Ponec 2006 
EPR Thermal lipid phase 
transitions 
within membrane 
microenvironment 
Rotational mobility of spin labeled probe 
reflect membrane fluidity. Polarity of 
membrane microenvironment can be 
detected. 
 
Rehfeld et al. 1988 
Fluorescence 
anisotropy 
Structural 
arrangement of lipid 
matrix 
Reorientation of excited fluorescence probe 
in lipid matrix reflects molecular packing of 
the lipids, and can be measured as an 
alteration of polarized emission and life-
time. 
Pechtold et al. 1998 
 
Porous pathway domain 
  
Impedance Skin electrical 
resistance 
 
Increased lipid disorder causes alteration in 
skin resistance  
 
DeNuzio and Berner 1990 
Kontturi et al. 1993 
Differential scanning calorimetry (DSC), differential thermal analysis (DTA), fourier transformation infrared 
spectroscopy (FTIR), attenuated total reflectance (ATR), small angle X-ray diffraction (SAXD), wide angle X-ray 
diffraction (WAXD), electron diffraction (ED), electron paramagnetic resonance (EPR). 
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crystalline phase (Knutson et al. 1987; Bouwstra et al. 1991). In addition, the flux of 
water through the skin is increased at temperatures over T2 (Golden et al. 1987). The 
fluidization of the lipid chains is not complete following the T2 and a further gel to 
liquid crystalline phase transformation of protein-bound lipids in cornified envelope has 
been observed at T3 (Knutson et al. 1987; Bouwstra et al. 1992). On reheating 
transitions T2 and T3 typically coalesced into a single endotherm at temperature close to 
T2 (Gay et al. 1994). Irreversibility of T3 is related to denaturation of proteins in lipid-
protein complex in cornified envelope, and this transition is typically absent in free lipid 
extracts of SC (Bonte et al. 1997). Accumulation of permeation enhancers, such as 
terpenes, into the SC evokes disorder in the lipid arrangement and may cause reductions 
in the T2 and T3 transition temperatures (Cornwell et al. 1996; Chesnoy et al. 1999). 
Triclinic Orthorhombic Hexagonal
 
Figure 4. A schematic presentation of the lateral packing of lipids. 
 
   Impedance spectroscopy The electrical properties of the skin have been studied with 
impedance spectroscopy. Skin exhibits non-ohmic behaviour, meaning that the skin 
resistance decreases with increasing current or voltage (Kasting and Bowman 1990). 
The skin electrical impedance can be depicted as an equivalent circuit for epidermis, 
usually composed of resistors and capacitors (van Boxtel 1977; Yamamoto and 
Yamamoto 1977; Kalia and Guy 1995), in fact this has been suggested as representing 
an alternative method for measuring skin permeability (Kontturi et al. 1993; Kalia and 
Guy 1997). The high electrical resistance of the skin is related to low relative 
permeability of the SC (Sekkat et al. 2002). Skin electrical impedance can be used as a 
determinant of the efficacy of the permeation enhancers, which are known to alter the 
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skin barrier and therefore can change skin impedance (Karande et al. 2004 and 2005). 
Diffusion through skin “pores” has been claimed to explain transdermal transport of 
hydrophilic and ionic solutes. The current penetrates skin through aqueous pores and 
other hydrophilic channels, which means that impedance can be used to characterize 
ionic transport in human epidermis in vitro (Table I) (Kontturi and Murtomäki 1994). 
According to the porous pathway theory, permeability (P) has been related to electrical 
impedance (R) as follows: 
 
logP=logC-logR  (1) 
 
where C is a constant that depends on the solute radius and the structure of SC (Li et al. 
1998 and 1999). For transport via a porous pathway, the logP versus logR relationship 
should be linear with a slope of -1.  
 
2.3.2 Lipid organisation of human SC 
 
Lipids in human SC are known to be organised in two lateral phases with a repeat 
distance of approximately 6 nm (short periodicity phase, SPP) and 13 nm (long 
periodicity phase, LPP), corresponding to one bilayer (Broad) and one bilayer-
monolayer-bilayer (broad-narrow-broad), respectively (Bouwstra et al. 1991). This 
arrangement requires an equimolar mixture of cholesterol, free fatty acids and 
ceramides from the different classes; the FFAs promote the SPP formation and the 
presence of the free ω-hydroxyceramide EOS is crucial for LPP formation (Bouwstra et 
al. 1998a; Bouwstra et al. 2002; de Jager et al. 2004). Lipids in human SC are typically 
organised into orthorhombic (crystalline phase) lateral packing which is a dense 
structure with very low permeability (Bouwstra et al. 1992). FFA is known to induce 
the transition from a hexagonal sublattice to an orthorhombic sublattice when there is an 
equimolar mixture of cholesterol and ceramides (Bouwstra et al. 2002). 
   Based on the existing knowledge about lipid composition and organisation, some 
models to describe the lipid molecular arrangement in lamellar LPP have been 
introduced (Fig 2). Ceramides are highly hydrophobic molecules having long, straight 
and saturated aliphatic chains, and in the membranes they tend to induce the formation 
of non-bilayer phases (Veiga et al. 1999). However, in conjunction with cholesterol, 
FFAs and cholesterol sulfate they form ordered bilayer structures (Bouwsta et al. 2002). 
Ceramides are capable of hydrogen bonding which increase lateral interction between 
lipids and thus, impart greater stability to the lipid barrier (Pascher 1976). 
Swartzendruber et al. (1989) proposed the double bilayer arrangement caused by the 
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flattened lipid vesicles in the lamellar bodies where the randomly distributed long ω–
hydroxyceramides link the bilayers together (I in Fig 2). This model proposes an equal 
interfacial area for cholesterol and ceramides in a planar arrangement. More recently, 
Bouwstra et al. (2001) introduced the trilayer “sandwich model” consisting of two broad 
crystalline phases and a fluid phase located in the central narrow band (II in Fig 2). In 
comparison to the Swartzendruber model, this model is based on an approximately 
equal interfacial area of cholesterol and ceramides in a tail-to-tail arrangement. Only the 
linoleate moiety of ω–hydroxyceramides is distributed in a liquid sublattice, forming a 
central liquid lipid layer together with cholesterol. Forslind et al. (1997) introduced a 
model for the presence of liquid phases in SC (III in Fig 2). This so-called domain 
mosaic model assumed that the crystalline ordered lipid bilayer contains defects which 
are denoted by “grain borders” consisting of lipids in the liquid state. Cholesterol and 
lipids with short chain aliphatic hydrocarbons are thought to be present in the liquid 
domains, with the lipids with very long chains (over 20 carbons) found in the crystalline 
domains. Water molecules can diffuse across a bilayer through these continuous three-
dimensional liquid crystalline phases. 
 
2.4 Percutaneous absorption and its enhancement 
 
2.4.1 Drug permeation 
 
   Molecules have three potential pathways to pass from the skin surface to viable tissue; 
through sweat ducts, via hair follicles and across the intact SC (Barry 1991). Since the 
fractional area of these appendage routes is rather low (0.1%), the SC represents the 
major barrier for diffusion. In theory, transcellular permeation route across the 
corneocytes and the intercellular route via the lipid domain also exists, but due to the 
continuous lipid phase, the permeant in any case must diffuse also across the 
intercellular lipid layers. The high fraction of water insoluble proteins, densely packed 
in the corneocytes, makes them almost impermeable and the intercellular route is widely 
believed to represent the principal pathway for the permeation of both hydrophilic and 
lipophilic drugs (Potts and Gay 1992; Simonetti et al. 1995; Sznitowska et al. 1998). 
Therefore, the physical properties and the composition of the SC lipids are considered 
to be important for adequate skin barrier function. 
   Transport across the skin is a passive process and it can be approximated by Fick’s 
first law (Higuchi and Higuchi 1960), which can be simplified as follows (Schaefer and 
Jamoulle 1988): 
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CKp
h
CDKJss Δ=Δ=     (2) 
 
where Jss is the steady-state rate of skin penetration (flux) per unit area, D is the 
diffusion coefficient of the permeant in the skin, K is the partition coefficient of the 
drug between the skin and vehicle, ΔC is the concentration difference across the skin 
and h is the effective diffusion path length through the skin. Normally the drug 
concentration in the vehicle is much larger than the concentration under the skin and Eq. 
(2) is simplified to J = Kp x Cvehicle, where Kp is the permeability coefficient equal to 
(DK/h). Permeation is largely dependent on the physicochemical characteristics of the 
permeant. The most important physicochemical factor is the relative ability of the drug 
to partition into the polar and non-polar domains in the lipid lamellae. Ideally a drug 
should have a low molecular mass (< 500 Da), adequate solubility in oil and water and 
an optimal octanol/water partition coefficient (logP 1-4) (Potts and Gay 1992). 
According to Eq. (2) drug permeation can be improved by disrupting the barrier of the 
SC (smaller D), by increasing the effective concentration of drug in the vehicle (higher 
C) or by improving the partitioning between the formulation and the SC (higher K). 
Permeation in those skin areas with thin SC (small h) is higher than through the skin 
with a thicker SC. 
 
2.4.2 Permeation enhancement 
 
   The barrier of SC slows down the permeation of the drugs across the skin and 
therefore it is difficult to reach clinically active levels of drug in the plasma. Various 
techniques to enhance transdermal drug delivery have been introduced, such as the 
entrapment of drug into different vehicles such as liposomes (Kirjavainen et al. 1999), 
microemulsions (Lee et al. 2003), ethosomes (Touitou et al. 2000), and nanoparticles 
(Kohli and Alpar 2004).  The SC barrier can be overcome with microneedles (Martanto 
et al. 2004), and the drug can be driven across the skin with electrical methods e.g. 
iontophoresis (Hirvonen et al. 1993) and electroporation (Vanbever et al. 1997). 
   Chemical permeation enhancers are used to alter the lipoidal matrix of SC 
(Kanikkannan et al. 2005). Ideally, the permeation enhancers work rapidly and 
reversibly to reduce the skin barrier, they are pharmacologically inactive and non-
irritating thus allowing drug permeation into the body, but prevent the loss of 
endogenous materials, and are compatible with drug and other exipients. Permeation 
enhancers with a wide variety of chemical structures have been evaluated, for example 
fatty acids, fatty alcohols, terpenes, pyrrolidones, Azone derivatives and surfactants 
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(Kanikkannan et al. 2005). These chemicals should be sufficiently similar to 
endogenous SC lipids to intercalate, but different enough to alter the structure in order 
to increase SC permeability (Golden et al. 1987). However, with permeation enhancers 
it is usually difficult to achieve satisfactory plasma levels without damaging the skin. 
   The lipid-protein-partitioning theory suggests that chemical permeation enhancers act 
by one or more of three main mechanisms in SC: altering the intercellular lipid domain 
or the intracellular protein domain or by increasing the drug partitioning into the skin 
(Barry 1991 and 2004). Many enhancers may combine these three mechanisms. The 
enhancers can modify the well-organised intercellular lipid domain by increasing the 
fluidisation and disorder of the crystalline phase when they become incorporated into 
lipid lamellae, which will facilitate drug permeation. Enhancers (oleic acid and Azone) 
may also become concentrated heterogeneously within the lipid domain, and induce 
enhancer pool within lipid domain, thereby causing defects in the lipid route of drug 
permeation. Good solvents, such as ethanol and DMSO, may extract lipids, making the 
SC more permeable via a formation of  aqueous channels. Some chemicals alter the 
polarity of lipid domain and thus increase the drug partitioning into the skin. Potent 
enhancers, such as ionic surfactants, may also act at protein structures, like desmosomes 
between corneocytes, to split the SC, or they may denaturate keratin or form vacuoles 
within the corneocytes. The appropriate choice of the vehicle components will increase 
drug partitioning into the skin by increasing the thermodynamic activity, or the escaping 
tendency, which may be reflected as a change in the ratio of drug concentration to its 
solubility in the vehicle. 
 
2.5 Microemulsions 
 
2.5.1 Structure and properties of microemulsions 
 
   Microemulsions are systems that are formed spontaneously when oil, water and a 
fixed mixture of surfactant/co-surfactant are combined. However, the microemulsion 
structure is only formed at specific ratios between these components, and once the 
composition is right, thermodynamically stable and low viscosity disperse solution is 
formed spontaneously. A simple change in the relative percentage of these components 
allows the formation of other colloidal structures such as regular emulsions, anisotropic 
crystalline hexagonal or cubic phases, and lamellar structures (Baroli et al. 2000). The 
low interfacial tension is crucial for the monodisperse droplet formation of 
microemulsions, and is achieved by adding a co-surfactant, e.g. short-chain alcohol, to 
the system. The low surface tension leads to subdivision of the dispersed phase into 
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very small droplets (below 140 nm) (Fig 5a), an increase in the number of droplets and 
an enlargement in the total internal surface area of particles in the microemulsion, which 
make the system transparent and thermodynamically stable (Tenjarla 1999). The 
structure of microemulsion may contain even equal amounts of oil and water phases and 
a high surfactant/co-surfactant content (20-80%). The oil and water components of 
microemulsion can be either in a continuous external phase or enclosed into the 
dispersed phase (o/w, w/o –microemulsions), when the surfactant and co-surfactant 
have a strong tendency of adsorption at the phase interfaces (Fig 5a). Although the 
microemulsions are thermodynamically stable systems, there are continuous diffusional 
processes and collisions at the interface of the droplets (Lam and Schechter 1987; 
Kreilgaard et al. 2000), but the equilibrium droplet shape and size is maintained. 
 
Figure 5. The microemulsion structures formed by oil phase, water phase, and surfactant and 
co-surfactant interfacial film (a), and mechanisms of drug release from microemulsion droplets; 
drug penetrates to skin only from the outer phase (b), droplets break down upon contact with 
skin and release the contents into the skin (c) or direct drug diffusion to the skin from a droplet 
(modified from Pappinen et al. 2005, with permission). 
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2.5.2 Means of increasing dermal drug delivery 
 
   The potential of microemulsions as topical formulations was first realized in the 1980s 
(Martini et al. 1984; Wang et al. 1987). Subsequently, the microemulsions have become 
an increasingly popular topic in the field of cutaneous drug delivery. Microemulsions 
have been shown to facilitate the cutaneous delivery of a wide range of both lipophilic 
and hydrophilic drugs in vitro and in vivo (reviewed by Kreilgaard 2002). When 
compared to emulsions, hydrogels and liposomes, it does seem that microemulsions are 
able to mediate increased percutaneous drug delivery (Kriwet and Müller-Goymann 
1995; Paolino et al. 2002). 
   Increased solubility Favourable solvent properties are related to large fractions of oil 
and water phases in the microemulsion, and high amounts of both lipophilic and 
hydrophilic drugs can be incorporated even into the same microemulsion system (Lee et 
al. 2003). This allows an increase in the concentration gradient across the skin, which 
facilitates drug permeation according to Fick’s law for diffusion (Higuchi and Higuchi 
1960). The drug is believed to be in equilibrium between the dispersed and continuous 
phase, according to the physico-chemical properties of drug and microemulsion 
components (Mrestani et al. 1998). 
   Drug release from a vehicle The thermodynamic activity of the drug, or escaping 
tendency from the microemulsion, is the true driving force in drug release from the 
vehicle into the skin. Maximal thermodynamic activity is achieved when there is a 
saturated solution, and the thermodynamic activity at a certain concentration can be 
described as the ratio between the real concentration and saturated concentration (Barry 
1989). Release of a drug from a vehicle is affected by its tendency to stay in the 
microemulsion components or disperse structures, and its tendency to partition from the 
vehicle into the skin. Overall, the drug release from microemulsions is a complex 
interplay between the properties of the drug, the vehicle and the skin barrier. 
   High mobility in the vehicle Microemulsions are known to be dynamic systems of 
continuously colliding, disappearing and newly forming droplets, which are affected by 
the flexibility of interfacial film and thus promoting high drug mobility in the vehicle 
(Lam and Schechter 1987; Kreilgaard et al. 2000; Lee et al. 2003). Enhanced drug 
delivery from the microemulsions is partly related to high drug mobility, allowing free 
diffusion of the drug in the vehicle which translates into faster drug diffusion to the skin 
surface and higher transdermal flux. The random movement of a molecule in an 
isotropic solution without thermal gradients is termed self-diffusion. Increased self 
diffusion of drug molecules in microemulsions is inversely related to the higher rate of 
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permeation across the skin and the lower viscosity of vehicle (Kreilgaard et al. 2000; 
Hua et al. 2004). 
 
2.5.3 Drug distribution mechanisms 
 
   The mechanisms of drug release from the microemulsion droplets and drug 
partitioning into the skin are not yet understood, but three possible explanations may be 
examined (Fig 5b-d). Relative contribution of different mechanisms may depend on the 
properties of the drug and microemulsion formulation. 
   There is always some drug distributed between inner and outer phases, and it may be 
possible that drug partitions into the skin only from the continuous phase. Subsequently, 
the absorbed drug is replaced by the drug release from the dispersed phase to the 
continuous phase, and the droplets function as drug reservoirs. This is supported by a 
study where it was shown that the water soluble Sudan dye, which was incorporated 
into water phase of o/w-microemulsion, did not penetrate through the skin (Gasco et al. 
1991). 
   Another possible mechanism is the droplet fusion in the skin surface. Since many 
components of the microemulsions are known to be permeation enhancers, they might 
interfere with SC lipids and improve drug permeation. Improved levels of drug 
permeation have been obtained by adding the enhancers into either the microemulsion 
phase during preparation (Gasco et al. 1991; Escribano et al. 2003) or directly into the 
ready made microemulsions (Rhee et al. 2001; Chen et al. 2004). 
   In the third mechanism, the large surface area of microemulsion droplets in contact 
with the skin surface provides a high local concentration gradient that facilitates drug 
permeation from the droplet interface to the skin (Kreilgaard et al. 2000; Paolino et al. 
2002; Chen et al. 2004; Sintov and Shapiro 2004). In this case, the disintegration of the 
droplet structure is not needed. Many drugs, such as prilocaine, lidocaine, ketoprofen, 
and triptolide, locate in the droplet interface in a same manner as the surfactant and co-
surfactant (Kreilgaard et al. 2000; Paolino et al. 2002; Sintov and Shapiro 2004; Chen et 
al. 2004). 
 
2.6 Organotypic keratinocyte cultures 
 
2.6.1 The construction of skin alternatives 
 
   Skin alternatives are typically categorised as epidermal models and full-thickness skin 
models (Table II). Epidermal models consist of epidermal cell layers and they are 
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constructed by culturing the keratinocytes on the surface of a suitable membrane, such 
as polycarbonate, or on collagenated membrane (Table II, Fig 6). In full-thickness skin 
equivalents, the keratinocytes are grown either on de-epidermized dermis removed from 
native intact skin or on dermal equivalents consisting of fibroblast cells embedded in the 
collagen gel (Table II). In all reconstructed skin models, the keratinocytes are allowed 
to proliferate and cover the surface of the membrane submerged on the culture medium, 
until the surface of the cells is raised to the air-liquid interface and thereafter, the cells 
are fed from below and exposed to air above, which resembles the clinical conditions. 
The skin cell models are cultured usually at 33-37 ºC, in humidified atmosphere at 5% 
CO2. The keratinocytes differentiate and stratify typically in two to three weeks into an 
epidermis, which closely resembles the native epidermal layers and the expression of 
epidermal differentiation markers. 
 
 
Figure 6. Schematic diagram of the rat epidermal keratinocyte organotypic culture (ROC). 
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Table II. Reconstructed epidermal skin models. 
Skin model Supplier Cell origin References 
Epidermis on filter   
 
SkinEthic 
 
SkinEthic laboratories,  
Nice, France 
NHK* 
 
Rosdy and Clauss 1990 
 
 
EST-1000 
 
 
CellSystems®,             
St Katharine, Germany 
 
NHK* 
 
 
http://www.cellsystems.de/englisch/ 
produkte/in_vitro_modelle/est1000/ 
estmain.html  
 RHE In-house model NHK* Poymay et al. 2004 
Epidermis on collagenated filter   
 
EpiDerm 
 
MatTek Corporation, 
Asland, USA 
NHK* 
 
Cannon et al. 1994 
 
 Episkin L'Oreal, Lyon, France NHK* Tinois et al. 1991 
 ROC In-house model REK cell line  Pasonen-Seppänen et al. 2001a 
Epidermis on human fibroblast populated collagen  
 
TestSkin® 
Apligraft 
LSE, Organogenesis Inc., 
Canton, USA 
NHK* 
 
Bell et al. 1991 
 
 LSE-high In-house model NHK* Watanabe et al. 2002 
 BHS In-house model NHK* Godwin et al. 1997 
 
ASC 
 
In-house model 
 
Transformed 
HaCaT cell line 
Specht et al. 1998 
 
 
AST-2000 
 
CellSystems®,               
St Katharine, Germany 
NHK* 
 
Noll et al. 1999 
 
 Cosmital In-house model (Wella) IHK* Nosser and Limat 1987 
 
Skin2ZK1300 
 
Advanced Tissue Sciences, 
La Jolla, USA 
NHK* 
 
Naughton et al. 1989 
 
 ASE In-house model NHK* Michel et al. 1995 
 CSS In-house model NHK* Boyce and Williams 1993 
 Other models In-house model NHK* Lee et al. 2000 
Epidermis on de-epidermised human dermis   
 RE-DED In-house model NHK* Ponec et al. 1997 
 Other models In-house model NHK* Prunieras et al. 1983 
    In-house model NHK* Kennedy et al. 1996 
IHK=Interfollicular human keratinocytes 
NHK=Normal human keratinocyte 
REK=Rat epidemal keratinocyte 
*Early 1st to 4th passage primary cells 
   
 
   Various models of skin equivalents have been developed and some of them are now 
available commercially (Table II), but the level of model documentation varies 
extensively. Most of the models are reconstructed from human keratinocytes, human 
fibroblasts and/or de-epidermised human dermis, and typically primary or early passage 
cells have been used. The final model properties are also affected by the culture 
conditions (medium composition, temperature and humidity), which are known to be 
important for cell differentiation and modulation of epidermal microenvironment (Gibbs 
et al. 1997; Ponec et al. 1997). Although useful, these models are difficult to prepare 
since freshly separated or early passage cells are needed. The availability of human skin 
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cells for the cultures is limited and their quality is variable, which decreases the 
reproducibility of experiments and leads to high inter-batch variation (Lotte et al. 2002). 
Therefore, continuous cell lines are attractive alternatives to the primary keratinocytes. 
However, the reconstruction of epidermis using established cell lines, such as the 
immortalised human keratinocyte line HaCaT, resulted in the formation of an 
incompletely differentiated epithelium (Ponec et al. 2000b). The use of rat epidermal 
keratinocyte (REK) cell line has overcome this problem, because it is a continuous cell 
line without cell transformation, and forms a tight and reproducible permeation barrier 
(Pasonen-Seppänen et al. 2001a and b). 
 
2.6.2 The barrier function 
 
   SC lipid composition The SC ensures the  barrier function of the skin (Scheuplein 
and Blank 1971). The formation of SC barrier in skin culture models proceeds in a 
similar manner as occurs in human skin in vivo. The process  includes extensive 
production of lamellar bodies, their extrusion at the stratum granulosum/SC interface, 
and their conversion enzymatically to more non-polar lipids of the SC. However, in the 
models, the extrusion of lamellar bodies is often incomplete and the lipid droplets are 
partly present both in the viable keratinocytes and the SC (Ponec et al. 2002). 
   Lipid analysis of some epidermal models has revealed the presence of all major lipid 
classes normally found in skin (Ponec et al. 2002). The lipid composition changes 
dramatically in the stratum granulosum/SC interface. SC is known to be the main 
barrier of the skin and therefore it would be more informative to study the lipid 
composition of SC rather than the whole epidermis. However, the SC lipid composition 
of only a few skin models has been reported: RE-DED, LSE and the in-house model of 
the human keratinocyte culture have been reported to contain higher amount of 
cholesterol (~66%), and much less ceramides (~27%) and FFA (~7%) compared to 
human skin (Bouwstra et al. 1995; Kennedy et al. 1996). The reconstructed skin models 
(EpiDerm, SkinEthic, Episkin, LSE, CSS, RE-DED) have been shown to contain higher 
proportions of ceramide 2, lower proportions of ceramide 5 and 6 than are present in 
human skin, and the absence of ceramide 7 (Ponec et al. 1997, 2000a and 2002). 
However, the supplementation of RE-DED medium with vitamin C and a mixture of 
fatty acids (palmitic, linoleic and arachidonic acids) resulted in a ceramide profile 
similar to that of native epidermis (Ponec et al. 2003). 
   SC lipid organisation Multiple broad lamellar lipid structures, similar to human skin, 
are typically formed in the intercorneocyte space of reconstructed skin modes. 
However, according to X-ray diffraction analysis, the long periodicity phase (LPP) with 
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a repeat distance of 12.6 nm, corresponding to 13.4 nm LPP in human skin, was only 
present in a few models (RE-DED, EpiDerm permeation model), whereas the SPP was 
present only in native tissue (Ponec et al. 2002). In addition, the lateral packing of skin 
models (RE-DED, LSE) have been shown to be significantly less ordered than is the 
case in human skin (Bouwstra et al. 1995). In skin models, the content of linoleic acid in 
ceramide 1 (EOS), the main structural component of LPP, is lower with this fatty acid 
largely replaced by oleic acid (Ponec et al. 1988, 2001 and 2003), which might explain 
the absence of LPP. Although the reconstructed models have been observed to contain a 
cornified protein envelope and its components, the presence of a lipid envelope 
covalently bound to a cornified envelope has not been widely studied. While Kennedy 
et al. (1996) and Pouliot et al. (1999) did not find such covalently bound ceramides in 
reconstructed human epidermises, Ponec et al. (2000b) was able to detect their presence 
in RE-DED in amounts comparable with those in native skin. 
   Drug permeation The SC is a major barrier to the uptake of drug molecules into and 
through the human skin, and the mechanistic principles for drug transport in the skin 
models are rather similar. In the cell models the water insoluble cornified envelope of 
the corneocytes is impermeable and the intercorneocyte penetration pathway dominates, 
as is a case in the native skin (Vicanová et al. 1999). In contrast to the native skin, the 
appendages, such as sweat glands and hair follicles, are absent in the models. However, 
the shunt pathway of drug absorption through appendages is of little relevance since the 
fraction of appendages in human skin is low (0.1%); only very large hydrophilic 
molecules may use this pathway as a primary permeation route (Hueber et al. 1994). 
   The currently available skin models function as a less efficient barrier than the native 
skin and the drug permeability is higher than in intact human skin in vitro, sometimes 
the difference is even 2-3 orders of magnitude (Fig 7). The SC of the cell models is 
about two times thicker than in the human skin, and in some cases it can be as much as 
10-fold thicker (Ponec et al. 2000a; Pasonen-Seppänen et al. 2001a). It seems that the 
less developed barrier function of the skin models is the most plausible explanation for 
the leakiness of the cell models relative to the intact human skin. The differences of 
permeability  are probably related to the differences in the formation of SC, e.g. 
incomplete lamellar body extrusion, presence of intracellular lipid droplets, differences 
in lipid composition and arrangement (Ponec et al. 2002). Unfortunately, usually only a 
small group of chemicals (1-4) have been tested in a single permeation experiment with 
the skin models. ROC is the most extensively evaluated model in drug permeation, 
since the permeabilities of 18 drug molecules with a variety of physicochemical 
characteristics have been reported (Suhonen et al. 2003). The permeability of this model 
is in the same range as human skin. In several skin models (EpiDerm, Episkin, RE-
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DED, BHS, ASC) the permeability ratio model/human skin was decreased with 
increasing logP. This suggests that the lipid pathway was more similar to the human 
skin than the polar pathway. This trend was not seen in the case of ROC, which seems 
to represent a similar barrier (1-5-fold ratio to human skin) for both lipophilic and 
hydrophilic drugs. It is impossible to draw any final conclusions about the validity of 
these models, perhaps with the exception of i.e. ROC, in terms of how well they assess 
drug permeability without performing much more experiments. Current data with most 
models is sparse. 
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Figure 7. The permeability ratio (skin model /  human skin) as a function of drug lipophilicity 
(logarithm of octanol-water partition coefficient; logP); EpiDerm (◦) (Asbill et al. 2000; Wagner 
et al. 2001; Zghoul et al. 2001; Dreher et al. 2002; Hammell et al. 2005; Schreiber et al. 2005; 
Schäfer-Korting et al. 2006), Episkin (×) (Dreher et al. 2002; Schäfer-Korting et al. 2006), 
SkiEthic (Δ) (Schmook et al. 2001; Schreiber et al. 2005; Schäfer-Korting et al. 2006), LSE (▫) 
(Ernesti et al. 1992; Nolte et al. 1993; Roy et al. 1993; Schmook et al. 2001), RE-DED (○) 
(Ponec et al. 1990; Boelsma et al. 2000), BHS (+) (Fuhrman et al. 1997; Godwin et al. 1997; 
Asbill et al. 2000), ASC (-) (Specht et al. 1998; Hoffmann and Müller-Goymann 2005; Winkler 
and Müller-Goymann 2002), AST-2000 (□) (Hoffmann and Müller-Goymann 2005), ROC (●) 
(Suhonen et al. 2003). 
 
   In conclusion, the permeation barriers of the skin models are generally less developed 
and more permeable to drug molecules than human skin. The SC accounts for barrier 
integrity by virtue of its specific lipid composition and organisation, but the SC of the 
skin models is largely unknown. The published investigations have revealed some 
differences in the lipid profile and thermotropic behavior of the cell models relative to 
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the skin. Permeation enhancers as major components of the topically applied 
formulations, appear to promote transdermal drug permeation by altering the lipid 
barrier of SC. However, little is known about the effects of permeation enhancers on 
cultured skin models. 
 
2.7 Chemical irritation 
 
   The official skin irritation tests based on OECD (1981) and EU (EC 1984) guidelines 
are modifications of the Draize test (Draize et al. 1944). In these animal tests, the 
substances are applied topically on rabbit skin and then physiological changes are 
scored. The changes, including erythema and edema, are used to classify the chemicals. 
Due to the ethical concerns of animal testing, these tests are obligated to be replaced in 
the cosmetic industry by alternative methods by the year 2009 (76/768/EEC, Feb 2003). 
Therefore, one of the most highly developed applications of commercial reconstructed 
epidermis models is in vitro prediction of the cutaneous irritancy of topically applied 
products. 
   Use of reconstructed skin models in chemical irritation The new EU chemicals 
policy, REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals), 
was launched in June 2007. REACH will give place new obligations on industry to 
manage the risks from chemicals, which are produced or imported into the EU in 
quantities more than one tonne per year, and to provide safety information for human 
health and the environment (REACH Regulation (EC) No 1907/2006 and Directive 
2006/121/EC). The registration will involve a high number of chemicals and alternative 
methods, such as skin models, will be very useful in the risk assessment of chemicals. 
The scientific policy of European Union aims to reduce, refine and replace animal 
experiments whenever it is scientifically feasible.  REACH legislation recommends the 
development and use of alternative methods for animal experimentation. 
    The cutaneous uptake of chemicals is the first step in the induction of skin damage 
and the keratinocytes are known to play a crucial role in the initiation and regulation of 
epidermal inflammation (Gröne 2002). The use of three-dimensional human 
keratinocyte cultures is the logical choice for the skin irritation tests because the test 
material will be applied directly to the surface of the SC. This should ensure the correct 
exposure conditions and concentrations that are similar to the in vivo situation. In vitro 
data on chemical induced irritation and cell cytotoxicity have been compared to in vivo 
data in several studies (Table III). Typically skin models are either incubated with the 
topically applied irritant during the whole experiment or pre-treated before the 
experiment. Irritation markers are either released into the culture medium underneath 
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the viable epidermis or they can be detected from keratinocyte cells with different 
techniques. The most commonly used irritation parameters include tests for cell 
viability (MTT, arman blue, neutral red-uptake), cell membrane integrity (e.g. LDH 
enzyme leakage), epidermal morphology and the release of proinflammation mediators 
(interleukins, tumor necrosis factor alpha (TNF-α)) and arachidonic acid metabolites 
(prostaglandins (PGE2, PGI2)). New methods of genomics and proteomics have been 
explored in attempts to find new biomarkers for skin irritation (Fletcher et al. 2001; 
Corsini et al. 2002). 
   Exposure to an irritant induces the release of inflammatory mediators as a primary 
contact reaction in the viable epidermis. Interleukin 1α is believed to be the main switch 
in the initiation of inflammation, since it is constitutively present in the keratinocytes 
and it is known to induce the expression both of itself and other interleukins 
(6,7,8,10,12,15,18,20), tumor necrosis factor α (TNF α) and interferons (α,β,γ) 
(Robinson and Perkins 2002). Cellular cytoplasmic enzyme leakage is another marker 
of irritation, which can be detected from the culture medium (Perkins et al. 1999). 
Several enzymes (e.g. LDH) are only released from leaky cells following membrane 
injury which is a rather more severe reaction to the irritants and more intense than 
inflammation but the cells may be still viable. Toxicity tests, indicating cell death, have 
commonly been used as irritation tests in the measurements of the cell viability. The 
MTT assay is based on the reduction of tetrazolium salt to formazan dye in active 
mitochondria, and either the percentual reduction in the cell viability, or the 
concentration (IC50) or time (ET50) that causes a 50% decrease in mitochondrial 
activity are presented (Cannon et al. 1994; Roguet et al. 1994; Doucet et al 1996). Also 
the histological changes evoked by the irritant on cell morphology can be assessed 
(Conquette et al. 1999). However, multipoint sampling as a function of time would 
require the release of irritation markers from living cells to the receiving medium. For 
that purpose, MTT test and morphological perturbation are not the best options because 
they are invasive methods. 
   A higher degree of standardisation of the various experimental protocols and 
endpoints, testing the skin irritation in vitro, needs to be achieved. Due to the ethical 
concerns about animal use, the validity of animal skins as models, and the need for 
efficient and cost effective preclinical test methods has set up the ECVAM (European 
Centre for the Validation of Alternative Methods) Skin Irritation Task Force to validate 
the relevant in vitro models for the acute skin irritation tests (Fentem et al. 2001). Two 
reconstructed human epidermis models (Episkin, EpiDerm), one human skin model 
(PREDISKIN), pig skin model, and ex vivo mouse skin model (SIFT) have been pre-
validated during 1999 and 2000. The pre-validation process includes protocol 
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refinement (phase I), protocol transfer between laboratories (phase II), and protocol 
performance (i.e. the reproducibility and predictive ability of the tests) (phase III). Only 
three models (Episkin, EpiDerm and SIFT) entered to phase III but none of the methods 
was ready to enter a formal validation study (to meet the criteria of test sensitivity and 
specificity >60% for correct classification, based on statistical data analysis). As a 
follow-up to the prevalidation, the ECVAM management team recommended that the 
protocols be refined, to incorporate the additional endpoints alongside the cytotoxicity 
testing and to develop a common protocol that could be used with all models (Zuang et 
al. 2002). The modified protocol for Episkin was recently introduced with the 
sensitivity and specificity >60%, and the addition of new endpoints, adenylate kinase 
(AK) and IL-1α, further improved these parameters (Portes et al. 2002; Cotovio et al. 
2005). When the Episkin cytotoxicity protocol was applied with the EpiDerm model, 
high sensitivity and specificity was achieved, and both models have been proposed for 
final validation (Kandárová et al. 2004 and 2005). Currently, the same protocol, 
differing only in minor technical details, has been applied to another human epidermal 
model not included in ECVAM pre-validation study, SkinEthic (Kandárová et al. 2006). 
The overall outcome of results obtained with the SkinEthic was very similar to that of 
earlier studies with EpiDerm and Episkin, and it is now ready for inclusion in a formal 
“catch-up” validation study. The management team did state that final validation would 
be evaluated during 2003 and 2004 (Botham 2004), but the results have not been 
reported yet. 
   In conclusion, there is a need for a valid in vitro model for assessment in vivo skin 
irritation. The development of simple and fast test systems to detect several different 
irritation responses using skin model would be useful. The present irritation tests are 
typically restricted to the analysis of one irritation marker at one time-point in a single 
culture. Studies with more markers and time-points would be more informative and 
reduce data variation. Multiple sampling during a single experiment would allow real-
time monitoring of both acute and delayed irritation responses. 
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3 AIMS OF THE STUDY 
 
   The primary focus of the present study was to investigate transdermal drug delivery 
and to characterise the rat epidermal keratinocyte organotypic culture (ROC) as a 
potential substitute for human skin in pharmaceutical studies. The specific goals of this 
research were as follows: 
 
1. To compare the structure of the ROC model membrane to human skin 
• by investigating SC lipid composition and thermal lipid phase transitions in 
ROC and human skin. 
 
2. To evaluate the ROC model in the assessment of the chemical skin irritation 
• by developing the method for detection of various irritation markers in single 
experiment 
• by developing the method for multiple-sampling during the experiment 
• by correlating the data to in vivo data 
 
3. To evaluate the functionality of the ROC cell model in the assessment of the topical 
drug formulations 
• by studying the drug penetration enhancement by various formulations, such as 
binary enhancer mixtures and microemulsions, on the barrier integrity of ROC 
and human skin. 
• by defining the mechanisms of microemulsions in percutaneous drug delivery 
using ROC and human skin. 
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4 MATERIALS AND METHODS 
 
4.1 Rat epidermal keratinocytes (REK) (I-III) 
 
   Baden and Kubilus (1983) originally isolated an epidermal keratinocyte (REK) cell 
line from newborn rats. The stock cultures were grown in Minimum Essential Medium 
(MEM) with 10% fetal bovine serum, 4 mM L-glutamine, 50 U/ml penicillin and 50 
µg/ml streptomycin sulfate at 37 °C in humidified 95% air/ 5% CO2. Cells were 
subcultured twice a week (1:10) using trypsin (0.05% w/v) - EDTA (0.02% w/v) 
solution from 0 to 40 passages, until keratinocytes lose the differentiation potential in 
the cell culture. 
 
4.2 REKs organotypic culture (ROC) (I-III) 
 
   For organotypic cultures, the REKs were seeded onto a collagen support and cultured 
at the air-liquid interface (Pasonen-Seppänen et al. 2001a and 2001b). Collagen was 
isolated from rat tail tendon, dried under UV light and the weighed amount of collagen 
was extracted with 0.1% (v/v) acetic acid for 48 hours at +4 ºC to give a final 
concentration of 3 mg/ml. Centrifuged collagen supernatant was mixed with EBSS 
(Earle’s Balanced Salt Solution), 7.5% sodium bicarbonate, 1 M sodium hydroxide at a 
volume ratio of 8:1:0.3:0.2, and 1 ml of the mixture was added on each polycarbonate 
Transwell culture insert (3 µm pore size, 4.7 cm2) and incubated overnight at 37 ºC in a 
humidified atmosphere. REKs were then seeded on collagen substrate (400 000 cells) 
and grown on Dulbecco’s Minimum Essential Medium (DMEM) with 10% fetal bovine 
serum, 4 mM L-glutamine, 50 U/ml penicillin and 50 µg/ml streptomycin sulfate 
submerged for 3 days at 37 °C in humidified 95% air/ 5% CO2. On day 4, the cultures 
were raised to an air-liquid interface and 1.5 ml of medium, supplemented with 40 
µg/ml L-ascorbic acid, was changed beneath the inserts every 2 days for the first week 
and daily thereafter. In the tests for irritation, REKs were cultured in phenol red free 
medium after the first week, to avoid any interaction with the LDH assay. 
 
4.3 Human epidermal membrane (HEM) (I, III, IV) 
 
   Excised human cadaver skin from the abdomen was obtained from the Kuopio 
University Hospital (Kuopio, Finland) with the permission of the Board of Medicolegal 
Affairs. Heating the skin sample in distilled water at 60 °C for 2 minutes separated the 
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epidermis. The epidermis was then peeled off and skin samples were dried at room 
temperature under gentle airflow for one to two days and stored at –20 °C for later use. 
 
4.4 SC isolated from ROC and HEM (I) 
 
   For the lipid analysis, SC was separated from epidermis. The fat tissue was removed 
from human cadaver skin, the skin sample was briefly rinsed with ice-cold hexane (Gay 
et al. 1994) and the dermal side of the skin sample was placed into 0.1% trypsin in PBS 
in 37 ºC for 2-3 days, until the epidermis was able to peel off. The epidermis of ROC 
was removed from the culture insert and collagen support. Trypsinated human skin 
samples and separated ROC epidermal membranes were briefly rinsed with ice-cold 
hexane and incubated with 0.1% trypsin solution for two hours at 37 ºC, for proper 
removal of all viable epidermal cells. Then the SC was peeled off and placed into 0.1% 
trypsin inhibitor solution to stop the activity of trypsin. Samples were finally rinsed with 
purified water, air-dried and placed in an exicator over a silica gel and under nitrogen 
for later use. 
 
4.5 Lipid analysis (I) 
 
4.5.1 SC extraction 
 
   About 40 mg of the dry SC from each donor and culture batch were extracted using 
three consequent extractions with chloroform/methanol in different ratios (2:1, 1:1, 1:2 
v/v) (Law et al. 1995), and finally with a single two-hour extraction with methanol. 
Thereafter, the covalently bound lipids were extracted from remaining tissue material by 
a mild sodium hydroxide saponification (Wertz et al. 1989). Evaporated samples were 
dissolved in chloroform/methanol (2:1 v/v), washed with 0.88% (w/v) KCl-solution 
according to the method of Folch et al. (1957) and finally dissolved in 
chloroform/methanol (2:1 v/v) at a concentration of 10 mg/ml prior to analysis. 
Covalently bound ceramide samples were dissolved in similar volume to corresponding 
free lipid samples. 
 
4.5.2 Thin layer chromatography (TLC) 
 
   Samples of 5, 10, 15 and 20 µl (50, 100 150 and 200 µg) of the free lipid extract and 
10 µl of covalently bound lipid extract were applied to the silica-gel coated (0.25 mm) 
thin-layer chromatography plates (20x20 cm). The lipids were separated by one-
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dimensional TLC by developing the plates sequentially with a) 
chloroform/methanol/water 40:10:1 (v/v/v) to 10 cm, b) chloroform/methanol/acetic 
acid 190:9:1 (v/v/v) to 16 cm and c) hexane/diethyl ether/acetic acid 70:30:1 (v/v/v) to 
20 cm (Law et al. 1995). Lipid standards (cholesterol, free fatty acid (C24:0), ceramide 
NS (C24:0), glycosylceramide and cholesterol sulfate) were run parallel. The plates 
were shortly dipped in CuSO4*7 H2O (7.5% w/v)/phosphoric acid (8% v/v) solution and 
then heated at 180 ºC for 8 minutes. Lipid spots of laser-scanned plates were quantified 
by Dot plot analysis of the ImageJ software (Wayne Rasband, National Institutes of 
Health, USA) and results were calculated using standard curves. 
 
4.5.3 Mass spectrometry 
 
   Ceramides separated by TLC were scraped from the plate, extracted with 
chloroform/methanol (1:1 v/v), washed using the Folch’s method (1957), evaporated 
and finally dissolved in chloroform/methanol (1:2 v/v) prior to analysis. Ceramides 
were analysed by LC-ESI-MS/MS, with identification of the ceramide classes being 
based on molecular weight, characteristic fragmentation pattern and elution time 
(Merrill et al. 2005). The molecular species of each ceramide subclass were analysed 
semi-quantitatively directly from the crude lipid extract by scanning the precursors of 
different sphingoid bases (Merrill et al. 2005). The analysis of different phospholipid 
classes and molecular species were carried out by MS using precursor ion or neutral 
loss scanning modes for identification and using internal standards for quantification 
(Koivusalo et al. 2001). 
 
4.5.4 Differential scanning calorimetry 
 
   In the DSC analysis the dry SC sheets were hydrated over a 27% NaBr solution for 48 
hour to evoke about a 20% hydration level. A small amount of tissue material (3-4 mg) 
was encapsulated into hermetically sealed 10 µl aluminium pans and heated, cooled and 
reheated again from 10 ºC to 110 ºC at 10 ºC/min using DSC 823e (Mettler toledo, 
Schwerzenbach, Switzerland) instrument. DSC curves were normalized to a sample 
weight of 1 mg and the transition temperatures were referred to the peak maxima 
determined in the heating runs. 
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4.6 Skin irritation (II, III) 
 
4.6.1 Test procedure (II, III) 
 
   The test chemicals (100 µl or 100 mg) were applied directly to the SC of the ROC 
culture and incubated for 30 minutes at room temperature. Then the chemicals were 
removed, the fresh medium (DMEM without phenol red) was replaced beneath the 
culture insert and the plates were placed on a microplate shaker in the incubator (37 °C, 
5% CO2). Samples (400 µl) were withdrawn from medium beneath the culture insert 
after 4 and 8 hours. For histology, the cultures were cut off after the last 8 h sample and 
stored in tissue fixative. For LDH measurement, the total available LDH enzyme in 
each ROC culture batch was determined by lysing two control (untreated) cultures 
before the experiment. Three parallel standard curves for LDH and two parallel standard 
curves for IL-1α were prepared at the beginning of each experiment. All samples and 
standards were frozen immediately at -70 C° to avoid enzyme and protein inactivation. 
Samples were analysed within two days after the experiment. 
 
4.6.2 IL-1α determination (II) 
 
   IL-1α release was determined using a rat IL-1α Duoset ELISA Development kit. 
Plates were prepared by coating a 96-well microplate with capture antibody (mouse 
anti-rat IL-1α), and thereafter the plate was treated with block buffer (1% BSA, 5% 
Sucrose in PBS). The plates were then incubated at room temperature for two hours 
with 100 µl of samples and two parallel standard curves with serial dilutions, and then 
for two hours with 100 µl of detection antibody (biotinylated goat anti-rat IL-1α). Then 
the plates were incubated for 20 min with 100 µl of streptavidin-horseradish-peroxidase, 
and thereafter for 20 min with 100µl of substrate solution (1:1 H2O2: 
Tetramethylbenzidine). The reaction was ended with stop solution (2N H2SO4) and 
absorption was determined immediately using a microplate set to 450 nm. Cumulative 
IL-1α release (pg) was calculated according to the standard curves. 
 
4.6.3 LDH determination (II, III) 
 
   LDH release was determined using the commercial CytoTox 96® Assay. In briefly, 50 
µl of each sample was transferred onto a 96-well microplate, 50 µl of reconstructed 
substrate mix (lyophilised diaphorase, lactate, NAD+, tetrazolium dye, Triton X-100) 
was added and plates were incubated for 30 min at room temperature protected from 
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light. The reaction was ended with 50 µl of stop solution (1M acetic acid) and 
absorbance was measured at 490 nm within one hour. The general chemical reactions of 
the CytoTox 96® Assay results in the conversion of tetrazolium salt into a red formazan 
product as follows: 
 
                                           LDH 
 NAD+   +  Lactate                       →              Pyruvate  +  NADH 
 
                   Diaphorase 
 NADH  +  Tetrazolium salt         →           NAD+      +  Formazan (red) 
 
Results were calculated according to standard curves and cumulative LDH release 
percentage was defined from Equation 3; 
 
 (Cumulative LDH (U/l)/ Maximum LDH (U/l)) x 100%  (3) 
 
4.6.4 Morphology (II, III) 
 
   Fixed ROC cultures were embedded in paraffin and stained with hematoxylin-eosin 
dye (Pasonen-Seppänen et al. 2001a). The morphology of chemical treated cultures was 
graded visually on a four class scale I-IV (II: Fig 2). 
 
4.7 Microemulsions (IV) 
 
4.7.1 Preparation of microemulsions 
 
   The oil phase (Epicuron 200, oleic acid and isopropyl myristate (IPM)), the water 
phase (PBS pH 7.4) and surfactant (Tween or Span) were mixed under magnetic stirring 
at room temperature (IV: Table 1). Then the co-surfactant (ethanol or isopropanol) was 
added gradually until the system was transparent. For the preparation of the 
microemulsion gel formulation (microemulsion F), Carbopol 940® was first mixed with 
water phase. Microemulsions A-E were saturated with estradiol (6.4-16.0 mg/ml) and 
microemulsion F was prepared to an estradiol concentration of 4.3 mg/ml. 
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4.7.2 Definition of microemulsion system 
 
   The size distribution of microemulsion vesicles was determined by quasi-elastic light 
scattering using Gaussian distribution analysis (Nicomp Submicron Particle Sizer, 
Model 370, Santa Barbara, CA, USA) and the phase systems (oil/water or water/oil 
microemulsions) were determined by measuring the conductivity (PW 9505 
Conductivity meter, Philips, England) of the system. 
 
4.8 Permeation experiments (I-IV) 
 
4.8.1 Control experiments (I-III) 
 
   To ensure the validity of the ROC culture in the course of experiments, the 
permeability coefficient of hydrophilic mannitol and lipophilic corticosterone were 
monitored periodically in the control experiments. The permeation studies were carried 
out using two-chamber diffusion cells (Side-by-side, Crown Glass Company, 
Sommerville, NJ, USA) thermostated to 37 ºC, with a 3 ml volume in donor and 
receiver compartments. The ROC insert, containing 3 µm porous polycarbonate 
membrane, was clamped between the compartments with an average effective 
diffusional area of 0.64 cm2. The receiver compartment was filled with fresh PBS (pH 
7.4) and the donor PBS was spiked with a [3H]-radiolabeled test substances (20 000-
40 000 dpm/ml). Constant magnetic stirring was maintained in both chambers during 
the experiment. Samples were withdrawn from the donor (10µl) and the receiver (200µl, 
which was compensated with fresh PBS) compartments, and the experiment was carried 
out for 3-5 days to ensure that the steady-state phase was attained (i.e., 3-5 times the lag 
time). The samples were mixed with 3 ml of scintillation cocktail (UltimaGold, 
Packard, Bioscience, Groningen, The Netherlands) and analysed with a liquid 
scintillation counter (WinSpectral 1414, Wallac, Finland). The permeability coefficients 
(P, cm/h) for drugs were approximated according to Eq. (2). 
 
4.8.2 Permeation enhancers (III) 
 
   The effects of various combinations of SDS:PP and MP:DPC on the permeation of 
lipophilic [3H]-corticosterone and hydrophilic [14C]-sucrose were investigated in the 
same diffusion cells using a double label detection technique (Fig 8). The permeation 
studies for both cadaver epidermis and ROC were carried out using side-by-side 
diffusion cells as in the control experiments with ROC (4.8.1). Briefly, hydrated (PBS) 
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samples of human skin and the ROC cultures, both on 3 µm porous polycarbonate 
supporting membrane, were placed between the side-by-side diffusion chambers. The 
membranes were pre-equilibrated with tested enhancer solutions in both sides of the 
samples for 2 hours, and the fresh solutions were changed every 30 minutes. After 2 
hour pretreatment with enhancer solutions, the donor was spiked with radiolabeled test 
substances. Samples were taken from the donor and receiver sides for 60 hours to 
ensure that the steady-state phase was attained and analysed with a liquid scintillation 
counter as was also done in the control experiment (4.8.1). The permeability 
coefficients (Kp, cm/h) for drugs were calculated according to Equation 2. 
CH3 O
S
O
O
O
-
Na
+
     
N
NH
 
 Sodium dodecyl sulphate (SDS)              Phenylpiperazine (PP) 
 
CH3 N
+
Cl
-
          CH3
N
O
 
 Dodecyl pyridinium chloride (DPC)          Methyl pyrrolidone (MP) 
 
Figure 8. Structure of permeation enhancers. 
 
4.8.3 Microemulsion formulations (IV) 
 
   The permeability of estradiol from microemulsions (IV: Table 1) through the human 
cadaver skin and ROC was investigated using Franz diffusion cells (Crown Glass Co. 
Inc., Sommerville, NJ, USA) thermostated at 37 ºC with an average effective diffusional 
area of 0.64 cm2. The receiver compartment was filled with 5 ml of 10% (w/v) 
hydroxypropyl-β-cyclodextrin(HβCD)-solution in PBS, to ensure the solubility of 
estradiol in the receiver phase during the experiment, and the epidermal samples were 
allowed to equilibrate between the diffusion chambers for about 17 hours prior to the 
experiment. One ml of formulation, saturated with estradiol, was pipetted into the donor 
compartment and samples were withdrawn from both the donor (10 μl) and receiver 
(700 μl, which was compensated with fresh 10% (w/v) HβCD-solution) chambers with 
long enough incubation times (24-70 hours) to ensure that the steady-state phase was 
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attained. The samples and standard solutions were analyzed using high performance 
liquid chromatography (HPLC) (I). The permeability coefficient (Kp, cm/h) for estradiol 
was calculated according to Equation 2, except that the cumulative amount of estradiol 
and the donor concentration was presented as µg and µg/ml, respectively. 
 
4.9 Impedance experiments (III) 
 
   The effect of permeation enhancers on skin electrical impedance was studied. Cadaver 
human skin and ROC were placed between the 7-hole (∅ 4mm) Teflon chamber 
system, which was constructed in the Technical Department of the University of Kuopio 
and were made to fit into the Transwell® culture plate well, and the parts were tightly 
clamped together with three screws (III: Fig 1). Silver chloride electrodes were placed 
into the receiver and donor chambers in contact with the PBS buffer, and sinusoidal 
voltage with an amplitude of 10 mV and frequency in the range of 0.05 Hz – 60 kHz 
was applied to the system. Skin electrical impedance was recorded before and after 22 
hours of skin treatment with permeation enhancers using a Solatron 1286 four-electrode 
potentiostat and Solatron 1170 frequency response analyser (Solatron Analytical, 
Hampshire, England), and impedance readings were presented in the form of a Nyquist 
plot. A previously introduced equivalent circuit, containing two resistors (R1, R2), a 
capacitor (C) and a constant phase element (CPE) (III: Fig 2), describing impedance 
spectrum of human skin was used (Kontturi and Murtomäki 1994). The skin membrane 
resistance, the descriptor of skin permeability, was defined as the diameter of the semi-
circle in the Nyquist plot (R1). 
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5 RESULTS 
 
5.1  Chemical composition of the SC lipid matrix (I) 
 
   SC lipid composition was compared between ROC and human skin. The dry weight of 
the cultured SC contained a similar amount of lipids (on average 15%) as human SC (on 
average 13%) (I). The lipid analysis revealed the presence of major lipid classes in the 
SC of ROC (cholesterol; 28%, ceramides; 52%, FFA 17%) in similar proportions as in 
human SC (cholesterol; 27%, ceramides; 51%, FFA; 21%) (I: Fig 2). Cholesterol sulfate 
is a minor, although important, lipid component of human SC (1.5%) and it is also 
present in the ROC (2.6%). Only trace amounts of phospholipids were observed in both 
membranes. 
   Although the total amount of ceramide in the native skin and ROC was similar, the 
relative amounts of the individual ceramide classes varied considerably (I: Fig 3). ROC 
contained significantly more ceramide NS than human skin, and ceramides NP and AP 
were absent. The amount of covalently bound ceramides (mainly EOS) was 75% lower 
in ROC than in the native skin, but on the contrary, the amount of free EOS was 60% 
higher in the culture. 
   The fatty acid chain length profiles of ceramides (NS, AS, NH, AH, EOS, EOP, EOH) 
between ROC and human skin were compared. In general, fatty acid chain lengths were 
in the same chain length range and both membranes contained long fatty acids, but once 
more a detailed analysis revealed differences in the relative amounts of individual chain 
lengths between the membranes (I: Fig 4). The most significant difference was seen in 
the case of ester linked fatty acids of EOS: ROC contained linoleic acid and oleic acid 
in a ratio 3:7 which is lower than that found in human skin (2:3). 
 
5.2 Thermotrophic behaviour of SC (I) 
 
   DSC analysis revealed four phase transitions (33, 50, 74, 86 °C) in the SC of human 
skin and three phase transitions (47, 68, 89 °C) in the ROC (I: Fig 5). The first small 
transition took place at 33 °C (T1) in the native skin but this was absent in the ROC. The 
second small transition was observed around 50 °C (Tx) in both membranes. The main 
lipid associated phase transition in human skin was seen at 74 °C (T2), but it took place 
at a lower temperature (68 °C) in the culture. The last peak (T3) was much smaller in the 
ROC and occurred at higher temperature (89 °C) than in the human skin (86 °C). 
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5.3 Skin irritation testing (II, III) 
 
5.3.1 Topically applied chemicals (II) 
 
   ROC cell model responded to the irritating chemicals by releasing LDH and IL-1α 
into the medium. Release data was correlated to scored changes of erythma (0-4) and 
edema (0-4) data in the literature (ECETOC 1995; Bagley et al. 1996) for rabbit skin in 
vivo (Primary irritation index (PII), total maximum value 8) (II: Fig 1). A correlation 
was found for both 4h and 8h in vitro data points. The chemicals were divided 
according to LDH and IL-1α release to irritants and non-irritants, like in EU 
classification, or to irritants, slight irritants and non-irritants, as in OECD classification. 
Threshold values for LDH and IL-1α release were solved using statistical analysis (II: 
Table 2) and the chemicals were classified based on these values (II: Table 3). Among 
the tested 12 chemicals, one was incorrectly classified based on the LDH-test (10-
undecanoic acid) and two in the IL-1α test (cis-cyclooctene, 2,4-xylidine) when EU 
criteria were used. According to OECD criteria, only one chemical was incorrectly 
classified with both methods: 10-undecanoic acid (in LDH assay) and 2,4-xylidine (in 
IL-1α assay). However, all tested chemicals were correctly classified based on at least 
one of the two tests, either in LDH leakage or in IL-1α release measurements. Overall, 
the eight-hour time point seemed to be slightly more predictive than that at four hours, 
and the best prediction was seen with LDH leakage test. 
   Morphological perturbations were graded visually into four classes (A-D) (II: Fig 2). 
The same chemicals, which were shown to induce LDH and IL-1α release caused also 
morphological alterations, with the exception of KOH, which did not cause any 
morphological changes (II: Table 3). Typical signs of irritation were lightly stained 
cytoplasm, condensed nuclei, cellular vacuolisation, eosinophilic cytoplasms, and 
blebbing. Overall, the morphological perturbation of the ROC epidermis mostly 
correlated with PII but seemed to be more easily induced than LDH leakage or IL-1α 
release. 
 
5.3.2 Topically applied penetration enhancers (III) 
 
   Permeation enhancers can be added to topical drug formulations to improve drug 
absorption, they are sometimes skin irritants. Their irritation effects can be tested using 
the ROC model. The irritation potential and permeation enhancer properties of five 
different formulations were investigated: 1.5% PP, 1% SDS:PP (04:06), 1% MP:DPC 
(06:04), 1% MP, 0.5% MP:DPC (08:02). On the basis of LDH release only 1% 
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MP:DPC 06:04 was predicted to be slightly irritating according to OECD criteria (see 
section 5.3.1), and all the other enhancer combinations were classified as non-irritants 
(III: Fig 8). Once again, more severe effects on epidermal morphology were observed 
and all permeation enhancers caused mild to moderate disturbances on ROC culture 
histology (III: Fig 8). However, the rank order of predicted irritation was similar for the 
LDH release and morphological perturbation. 
 
5.4 Permeation enhancer tests (III, IV) 
 
5.4.1 Enhancers in solutions (III) 
 
   Skin impedance spectroscopy and permeation experiments with lipophilic 
corticosterone and hydrophilic sucrose were used to probe the permeation enhancement 
effects of the enhancers (SDS:PP, MP:DPC; Fig 8) at several concentrations. Electrical 
characteristics of the ROC model were investigated using impedance and Nyquist plots. 
These Nyquist plots showed a similar depressed shape and the same equivalent circuit 
model (III: Fig 2) in the ROC model and in the human skin (III: Fig 3). The electrical 
resistance in the ROC was (95 kΩ), higher than in the human skin (55 kΩ) (III: Table 
1).  In general, the permeation enhancers decreased the resistance (R1) of both 
membranes, and the relative response of the ROC to permeation enhancers was 
comparable to that observed in human skin (III: Fig 4). Despite the high standard 
deviations, the values for electrical impedance between the enhancer treated native skin 
and the ROC were found to correlate. 
   A linear correlation of corticosterone permeability between ROC and isolated human 
skin was obtained, while the relationship of sucrose permeation was curved (III: Fig 6c 
and d). However, the maximum permeability coefficients were rather similar in both 
membranes for both solutes. ROC was more sensitive to the less potent permeation 
enhancers than human skin, especially in the case of sucrose. 
   In general, the drug permeability was increased with decreasing skin electrical 
resistance (R1) in both enhancer treated membranes (III: Fig 7). However, in human 
skin the correlation between skin resistance (R1) and permeability was not linear (III: 
Fig 7b). In contrast, the altered electrical resistance of the ROC model showed linear 
correlation with permeability of both solutes, except for one outlier (1.5% phenyl 
piperazine) that markedly increased drug permeation without any significant effect on 
electrical impedance (III: Fig 7a). 
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5.4.2 Microemulsions (IV) 
 
   All tested microemulsions were observed to be effective transdermal vehicles for 
estradiol. Formulations were defined to be o/w microemulsions and the droplet sizes of 
the microemulsions A, B, C, D, and E were determined to be about 10, 1, 1, 2 and 5 nm, 
respectively (IV). The permeation data in human skin showed that the microemulsion 
formulations increased the flux of estradiol 200-700-fold above the control, but the 
permeability coefficients were decreased by 5-18 times (IV: Table 2). In addition, 
microemulsions improved the solubility of estradiol by 1500-fold compared to control 
(PBS). Similar observations were made with ROC. The permeability of ROC was 1.3-
8.3 times higher than that of human skin (Table IV), and the tested microemulsions 
altered the electrical impedance of ROC 1.7-6.2 times more than that of human skin. 
 
Table IV. The permeability of estradiol (Kp) from formulation through human skin (HEM) and 
ROC, and the alteration of membrane electrical impedance by microemulsions 
(EFImp=R10h/R122h).  
 
Microemulsion HEM ROC   ROC/HEM  
 Kp (x103cm/h) EFImp  Kp (x103cm/h) EFImp  Kp EFImp 
         
A 0.7 (0.4) 4.0 (2.5)  2.0 (1.3) 21.9 (15.9)  2.9 5.5 
B 0.6 (0.2) 5.8 (4.2)  2.6 (1.0) 42.3 (27.4)  4.4 1.7 
C 0.5 (0.1) -  4.2 (1.1) -  8.3 - 
D 0.6 (0.3) -  0.8 (0.1) -  1.3 - 
E 0.2 (0.1) 5.1 (3.1)  0.3 (0.1) 31.9 (18.7)  1.4 6.2 
SDs presented in parentheses 
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6 DISCUSSION 
 
6.1 Lipid composition and lipid organisation of SC in ROC 
 
   It is generally accepted that the diffusion barrier for xenobiotic permation across the 
skin is located in the intercellular lipid region of SC. The structural organisation of the 
lipids in the SC is responsible for its exceptional barrier properties. Therefore, it is very 
important to characterize the lipid profiles of artificial SCs in order to assess their 
validity as models. 
   Our findings revealed that the major lipid classes of the human SC, cholesterol, 
ceramides and free fatty acids, were also present in the ROC at approximately similar 
quantities as found in human skin (I: Fig 2). Moreover ROC and human skin seem to 
form a rather similar acyl chain lengths of ceramides (16 to 30 carbons). According to 
X-ray diffraction studies, the lipids in intact human SC are highly ordered as 
orthorhombic lateral packing domains and the lipids form 13.4 nm (LPP) and 6.4 nm 
(SPP) lamellar phases (Bouwstra et al. 1991 and 1992). A similar distinct orthorhombic 
arrangement has been observed in novel equimolar lipid mixture of these three main 
lipid classes with 13 nm LPP and 5.3 nm SPP (Bouwstra et al. 2002). The lipid 
organisation of ROC was not directly studied, but the presence of these essential lipid 
components in the ROC in similar amounts with human skin appears to confer on the 
ROC model the natural SC like lipid arrangement model. 
   If esterified ω–hydroxysphingosine (EOS) is not in the ceramide pool, the appropriate 
molecular organisation of LPP structures is not obtained (Bouwstra et al. 1998a; de 
Jager et al. 2004). The similarity of the EOS content in the ROC and human skin is 
further evidence for the presence of proper lamellar packing of lipids in the cell model 
(I: Fig 3). In the human SC, the EOS has an exceptional structure in which the linoleic 
acid (C18:2) is ester-linked to an ω–hydroxy fatty acid with a chain length of 
approximately 30-32 carbons (Fig 3). Linoleic acid is an essential fatty acid that must be 
obtained from the diet. When there is a deficiency of essential fatty acids, the oleate 
content in EOS is increased at the expense of the linoleate (Wertz et al. 1983). This 
causes a strong reduction in the barrier function of the skin (Hansen and Jensen 1985; 
Wertz et al. 1987). Mass-spectrometric analysis of the ceramides of ROCs displayed a 
lower linoleic acid content (42%) compared to the human SC (64%) (I: Fig 4). This is 
typical for other skin models as well (Ponec et al 2003). This may be related to the more 
disordered lamellar arrangement and lesser SC integrity. Serum (FBS) in the culture 
medium of ROC contains only low amounts of linoleic acid. The addition of linoleic 
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acid into culture medium would have increased its ω–hydroxyceramide content and 
therefore could have improved the lipid order and SC integrity. 
   The ceramide analysis of ROC revealed a higher proportion of ceramide NS compared 
to human skin (I: Fig 3). This is the most abundant ceramide in the epidermis. On the 
contrary  the ceramides AP (CER6) and NP (CER3) were absent in the ROC. According 
to current knowledge, all the major sub-fractions of ceramides are assumed to be 
generated from glucosylceramides (Holleran et al. 1994), but the phosphosphingolipid 
sphingomyelin is a precursor for two ceramides, NS (CER2) and AS (CER5) (Uchida et 
al. 2000) (Fig 9). The overproduction of NS in the ROC may be related to higher 
enzyme activity in the sphingomyelin-dependent pathway. Nevertheless this does not 
affect AS synthesis, since its production in the model was comparable that of human 
skin. Sphingomyelin is known to be degraded enzymatically by at least two distinct 
enzymes, the aSMase and another SMase isoform with a more neutral pH optimum. 
These enzymes are involved in NS and AS synthesis (Merrill et al. 1990). Therefore the 
differences in the levels of these enzymes between ROC and HEM may explain the 
accumulation of NS in the ROC. SMase activity could be detected from homogenated 
tissue material with Amplex Red Spingomyelinase Assay Kit (Molecular Probes Inc., 
Eugene, OR). The gene of murine SMase is known to be almost identical to the human 
enzyme (Otterbach and Stoffel 1995). The absence of AP and NP could be related to 
some defects in the synthesis of phytosphingosine base, but since EOP was detected this 
cannot be the explanation. The absence of these ceramides cannot be explained by the 
different cell origin because also rat keratinocytes are known to generate these 
ceramides (Wertz et al. 1984). 
   The highly cross-linked protein surface of the corneocyte is surrounded by a 
covalently bound lipid envelope (Candi et al. 2005). Morphological studies have 
reported that the ROC contain cornified protein envelopes and also the characteristic 
components of the envelope, such as keratin filaments, involucrine and filaggrin 
(Pasonen-Seppänen et al. 2001a). Covalently bound ceramides, mainly EOS, probably 
serve as a template for the formation of lipid lamellae in the extracellular space. Our 
findings revealed that there were lesser amounts (1/3) of covalently bound ceramides in 
the ROC than in the human SC (I: Fig 3). This might reflect some defects in the 
differentiation of ROC keratinocytes. This might be important for SC integrity, but so 
far the relationship between the bound lipids and the barrier function is not well 
established (Meguro et al. 2000). 
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Figure 9. Synthesis pathway of ceramides (based on the results of Holleran et al. (1994) and 
Uchida et al. (2000)). A scheme representing postulated site for increased enzyme activity, 
which caused over-expression of NS (CER2) in ROC (bold arrow). 
 
   Thermal changes in SC can provide information on structural alteration within the 
sample. In the present study four endothermic transitions related to lipids in human skin, 
i.e. at 33 (T1), 50 (Tx), 74 (T2) and 86 (T3) ºC and three phase transitions in the ROC, 
i.e. at 47 (Tx), 68 (T2) and 89 (T3) ºC were observed in DSC analysis (I: Fig 5). On 
reheating, the T1 and Tx transitions were irreversible and transitions T2 and T3 coalesced 
into a single endotherm in both membranes. In the literature this kind of phase behavior 
is typical for skin samples. The absence of T1 in ROC may reflect the differently 
distributed lipid domains during the keratinocyte differentiation or the absence of 
sebaceous lipids in the model (Golden et al. 1986; Bouwstra et al. 1992). The gel to 
liquid crystalline phase transition (T2) took place at lower temperature (at 68 ºC) 
compared to the human skin (at 74 ºC). Since the amounts of cholesterol, ceramide and 
FFA were similar in both membranes, the lower T2 transition in the ROC is presumably 
attributed to the greater disorder in the lamellar lipid phase of the ROC. The alteration 
in the T2 transition has also been observed in enhancer treated SC (Cornwell et al. 1996; 
Chesnoy et al. 1999; Al-Saidan 2004). Slightly different ceramide profile and the 
absence of some ceramides, e.g. a higher amount of oleic acid residues in the esterified 
ω–hydroxysphingosines, and the lower amounts of covalently bound ceramides may 
alter the lipid organisation in the ROC SC and subsequently  lower the T2 transition. 
The T3 transitions were absent in the thermograms of free lipid extracts as well as in the 
Serine + Palmitate
Sphingoid base
Ceramide, acylceramide
CER 2,5 CER 1,3,4,6-9 
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second heating of SC samples (data not shown), and therefore it was related to phase 
transition of covalently bound ceramides. This occurred at a higher temperature in the 
ROC (89 ºC) than in the human skin (86 ºC). The enthalpy of this peak was significantly 
less in the ROC than in the human skin, suggesting that there may be a smaller amount 
of covalently bound lipid in the ROC than in the skin. This is also supported by the TLC 
data. 
 
6.2 Evaluation of skin irritation with ROC 
 
   It is an appealing but challenging goal to develop in vitro methods that would permit 
the prediction of the potential irritation by the chemicals to the human skin in vivo. One 
problem is that only a few studies have been done on human skin in vivo due to ethical 
concerns. The reliability of these results is often questionable, because the experiments 
are usually stopped should there be any severe reaction. Therefore, comparisons 
between in vitro data and animal data are more common, despite the differences from 
the human skin (Nixon et al. 1975). The official skin irritation tests are still based on 
animal data (OECD 1981; EU 1984), but the challenge is to identify and validate 
relevant in vitro endpoints for the prediction of skin irritation in vivo. Before applying 
these in vitro methods and attempting to correlate the biomarkers with in vivo data, 
several points must be considered. These factors include the possible interference of the 
test compounds with the biomarker assay, method of test compound application, 
relevance of the in vitro end point, and exposure time. 
   In our study, ROC was identified as a useful cell system for testing the skin irritation 
potential of chemicals, and we developed test protocols for such applications (II). We 
tested membrane integrity (LDH), cell inflammation (IL-1α), and culture morphology as 
potential endpoints of irritation,  since these are the first evident signs when cells are 
exposed to a toxin (Danpure 1994; Gröne 2002). Pretreatment of the ROC culture with 
chemicals induced IL-1α synthesis and LDH release from the cells into the culture 
medium. This approach can enable multipoint sampling from the medium without any 
physical contact with the culture. The protocol allows also the analysis of both acute 
and delayed effects, because the culture can be maintained viable for days after the 
exposure to irritants. This is an important feature as chemicals are known to induce skin 
irritation at different rates (Fentem et al. 2001). 
   In our study, the chemically induced release of LDH and IL-1α was first correlated to 
in vivo data (PII) and the best correlation was obtained with 8 hour pretreatment (II: Fig 
1). Good correlations between in vitro release of LDH / IL-1α and human skin irritation 
data have been reported for EpiDerm cultures that were exposed to irritants for 20-hours 
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(Perkins et al. 1999; Robinson and Perkins 2002). However, the extension of incubation 
period from 18 to 48 hours tended to decrease the IL-1α concentration in the medium, 
which is related to degradation of the cytokines during the experiment (Cotovio et al. 
2005). Therefore, the correlation of cytokine release to in vivo data after 20 hours would 
be inaccurate. Likewise, the LDH enzyme is also reported to become inactivated in the 
medium (Eun and Shu 2000), which is in line with our observations. We managed to 
minimize degradation of LDH and IL-1α in the samples by careful sample preparation 
and storage, but their partial degradation in the culture during the experiment cannot be 
prevented. Therefore, this natural degradation of cytokines and enzymes may 
complicate the studies of delayed irritation reactions. 
   Several mechanisms, such as inflammation, membrane alterations, and cell death, are 
involved in the chemical induced irritation. Therefore, suitable endpoints and exposure 
times must be assessed to provide relevant information. One irritation marker may not 
predict correctly the responses to irritants and non-irritants, and, thus, analysis of 
multiple biomarkers can improve the reliability of the predictions and classifications of 
chemicals. In the present study, eight hour exposure was the optimal timing for both 
irritation markers (IL-1α, LDH) and also the morphological alteration was most severe 
at this time point (II: Table 3). All of the biomarkers in our study (IL-1α, LDH, 
morphology) classified the chemical irritation almost correctly to the in vivo data (EU 
and OECD); out of twelve chemicals only two compounds (cis-cyclooctene and d-
limonene) were incorrectly classified using the IL-1α release assay, one compound (10-
undecanoic acid) using the LDH leakage assay, and one irritant (KOH) did not cause 
any morphological changes (II: Table 3). However, all of the chemicals were classified 
correctly at least by one biomarker. Although we classified the compounds separately 
according to each irritation marker, it might be more reliable to pool information from 
different endpoints. Scoring systems that take into account the overall changes of 
biochemical and morphological parameters have been introduced, but these crude 
classifications are not very comprehensive and sophisticated (de Brugerolle de 
Fraissinette et al. 1999; Medina et al. 2000; Tornier et al. 2006). Data of multiple 
irritation markers can be better utilized by developing prediction models based on 
multivariate descriptive statistics (Faller and Bracher 2002). However, this kind of 
analysis requires testing of more than 12 chemicals. 
   The commercial skin model data of the same 12 tested chemicals are available (Table 
V). In the EpiDerm and Episkin test protocols, chemical irritation was studied using the 
MTT test, while in the test system of SkinEthic, the combined information from MTT 
assay, IL-1α release, and culture morphology was used (Fentem et al. 2001; Cotovio et 
al. 2005; Tornier et al. 2006). ECVAM has recommended harmonisation of the irritation 
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test protocols for skin models (Zuang et al. 2002) and therefore EpiDerm and SkinEthic 
have also been tested using the Episkin protocol (Table V). In comparison to these 
commercial models, the ROC seems to follow more correctly in vivo data (EU): 1-2 
chemicals were incorrectly classified with ROC and 3-4 chemicals with other models 
(Table V). Moreover, the commercial skin models and tested protocols (except 
EpiDerm protocol) seem to be over-sensitive, since most of the chemicals (9) were 
classified as irritants. More severe effects may be related to the less efficient permeation 
barrier, since the barrier will hinder more efficiently the transport of an irritant to viable 
epidermis and therefore the barrier function regulates the level of irritation. The 
permeability barrier of the ROC model is reported to be more efficient than in other 
models (Fig 7) which may explain the better classification reslts. The superior 
assessment of irritation by the ROC model compared to the other skin models may also 
be related to the use of cytokine and enzyme markers, since these biomarkers represent 
the early stage responses. Irritant compounds induce IL-1α release and synthesis very 
rapidly, as well as LDH leakage which is a marker of membrane injury. On the contrary, 
the MTT test is based on cell viability and death. In addition, the incubation times in 
MTT tests are often much longer (42 hour) than in ROC protocol (8 hour). 
 
Table V. Comparison of chemical irritation classification between rabbit skin (PII, EU) and 
cultured skin models (EpiDerm, SkinEthic, EpiSkin and ROC). 
 
 
aPrimary Irritation Index; bI = irritant, NI = non-irritant; cMIP (meanET50 for 20% SDS/meanET50 for 
chemical) ≥ 8, test chemical is predicted to be I; dMultiple endpont analysis of MTT, IL-1 and culture 
morphology after 4 hour incubation with chemicals (Tornier et al. 2006); eIf cell viability in MTT test ≤ 
50%, test chemical is predicted to be I. 15 min pretreatment with chemical followed by 42 hour 
incubation period (Kandarova et al. 2005; Cotovio et al., 2005); fIf LDH release ≥ 50%, test chemical is 
predicted to be I. 30 min pretreatment with chemical followed by 8 hour incubation period; gIf IL-1 
release ≥ 180 pg, test chemical is predicted to be I. 30 min pretreatment with chamical followed by 8 hour 
incubation period; hA=normal histology, B=rather normal histology with some apoptotic cells, 
C=epidermal degeneration, D=severe epidermal degeneration or cell death. 30 min pretreatment with 
chamical followed by 8 hour incubation period. 
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6.3 Effects of permeation enhancers and formulations on barrier integrity of ROC 
 
   It is a challenging task to develop a cultured-based skin model with similar 
permeation profiles as the human skin. At a present, all of the developed skin models 
have been more leaky than the intact human skin (Fig 7). The overall barrier function of 
the ROC model is the best so far examined, and it has been more thoroughly 
characterised than the barrier of the other models. Permeation studies with 18 solutes 
with logP values ranging over 8 orders of magnitude exhibited permeability coefficients 
of 0.3-5.2 fold compared to the values obtained with isolated human cadaver epidermis 
(Suhonen et al. 2003). Compared to human skin, the permeability coefficients of 
corticosterone and sucrose in the ROC were reported to be 1.7-fold and 0.7-fold, 
respectively. In the present study, the permeability coefficients of corticosterone and 
sucrose in the ROC treated with 16 SDS:PP and MP:DPC permeation enhancer 
formulations were 1.0-3.1 and 1.4-46.3 times higher than those encountered in human 
skin, respectively (III). This result indicated that the ROC responds more easily than the 
human skin to exposure to permeation enhancers. However, the solvent of the 
formulations, 50% EtOH/PBS, alone caused higher drug permeation (3.1-fold for 
corticosterone and 15.4-fold for sucrose) in the ROC than in human skin (III: Table 1). 
Otherwise, the permeability values for corticosterone (human skin 0.4-10.9 (10-3 cm/h); 
ROC 0.9-11.5 (10-3 cm/h)) and sucrose (human skin 0.02-6.0 (10-3 cm/h)); ROC sucrose 
0.5-8.4 (10-3 cm/h)) in enhancer solutions were rather similar as those found in human 
skin (III: Fig 6c and d). 
   Permeation enhancers evoke disorder in the lipid matrix of the SC, and the severity of 
this disruption of the lipid organisation can be estimated with drug permeation studies. 
A lipophilic compound, corticosterone (LogKoctanol/water 1.94), is often used as a 
surrogate of the lipid pathway in the SC, whereas the hydrophilic solute, sucrose 
(LogKoctanol/water -3.7), represent a marker for the aqueous porous permeation pathway. 
The correlation of the values of corticosterone permeation between the membranes is 
evidence that there are similarities in the lipoidal route of permeation in the SC of the 
ROC and human skin (III: Fig 6c). This is in line with the results of lipid analysis 
which demonstrated the similar lipid compositions in the ROC and the human skin (I). 
Only the most effective enhancers were able to significantly increase the permeation of 
sucrose in the human skin, while most formulations improved its permeability in the 
ROC (III: Fig 6d). This observation may be related to the less tight organisation of 
lipids in SC of ROC, which may subsequently be more readily perturbed and create new 
polar permeation routes. As a hydrophilic molecule, sucrose is more dependent on the 
polar permeation routes, while the lipophilic compound, corticosterone, is transported 
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via the lipoidal permeation pathway. The porous pathway theory (Li et al. 1998 and 
1999) indicates similar transport pathways for the permeant and conducting ions, and 
this should lead to slope of -1.0 in the plot of sucrose permeability vs skin impedance 
(Eq. 1). This was the case in the human skin but not in the ROC (slope -0.61) pointing 
to the presence of additional pathways (III). 
   Microemulsions were demonstrated to be potential vehicles for improved topical 
delivery of estradiol (IV). The superior transdermal transport was mainly due to 1500-
fold improvement in the solubilization of estradiol by microemulsions (IV: Table 2). 
This is in line with other reports with different solutes (Trotta et al. 1997; Alvarez-
Figueroa and Blanco-Méndez 2001). In the present study, the increased solubilization 
was explained by the solubility of estradiol in the individual microemulsion components 
rather than any specific microemulsion structure as such (IV: Fig 3). Subsequently 
Subramanian et al. (2005) reached the same conclusion. 
   Drug delivery from microemulsions can take place via three hypothetical mechanisms 
(Fig 5): (i) the drug penetrates only from the outer phase and the microemulsion 
droplets act as drug reservoirs, (ii) the droplets break down upon contact with the skin 
and they release the microemulsion components into the skin or (iii) the high density of 
droplets in the microemulsion permits drug diffusion from the inner phase when the 
droplet is in contact with skin surface. Probably all of these mechanisms are involved to 
some extent. The mechanisms (i) and (iii) should be quite similar for the ROC and 
HEM, because their lipid compositions (I) are so similar. Therefore, partition 
coefficients of estradiol were similar between the microemulsion and the SC of the 
human skin and ROC. However, the permeability coefficient of estradiol administered 
in the microemulsions was not the same: 1.3-8.3-fold higher permeation was observed 
in the ROC than in the HEM (Table IV). The explanation for this descrepancy may be 
related to mechanism (ii) in which both the drug molecule and the microemulsion 
components are assumed to penetrate into the skin. Interaction studies of the 
microemulsions with the human skin (DSC, FTIR) have revealed penetration of 
microemulsion components into the skin where they may act as permeation enhancers 
(Dreher et al. 1997). Many components of microemulsions in the present study (IV) 
(oleic acid, IPM, Spans and Tweens) are known to promote the permeation of drugs into 
the skin (Kim et al. 1996; Goldberg-Cettina et al. 1995; López et al. 2000). However, 
they probably interfere with SC lipid matrix to different extents thereby causing 
different permeability in the ROC and HEM. The permeation coefficient of estradiol in 
Tween containing microemulsions (D and E) seems to be the same in both membranes 
(Table IV). On the contrary, the Span based microemulsions (B and C) showed higher 
permeabilities in the ROC than in the HEM (4.4 and 8.3-fold). This was especially the 
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case with microemulsion C, which differed from microemulsion B mainly in its 12% 
IPM content. However, IPM alone was not responsible for the higher permeation in the 
ROC since microemulsion A displayed only a 2.9-fold difference to HEM and this 
preparation contained 25% IPM. The different responses of enhancers on the membrane 
integrity of ROC and human skin cannot be exclusively related to the individual 
components of the microemulsions, and there are probably also other mechanisms 
involved, such as synergistic enhancer effects. Overall, the ROC responds more easily 
than the HEM to the actions of microemulsions, like it does in the case of binary 
permeation enhancer mixtures (III). 
 
6.4 The value of ROC in comparison to human skin in drug development and 
chemical testing 
 
   The focus of the present study was to evaluate the ROC as a potential substitute for 
human skin on the laboratory scale, and therefore the comparison was made with human 
skin instead of rat skin. On the other hand, possible differences between the human and 
rat keratinocytes, which may influence the final results, should be considered in 
research terms. In the present study, the choice of tested irritation markers (LDH, IL-1α) 
was justified since those markers are known to be produced both in human and rat 
keratinocytes (Glass and Doyle 1972; Babu et al. 2004), and furthermore, they exhibited 
a good correlation to in vivo data. The slightly more leaky permeability barrier of ROC 
compared to human skin cannot be explained by cell origin, since the rat skin has been 
reported to be significantly more permeable than human skin (Suhonen et al. 2003; van 
Ravenzwaay and Leibold 2004). The absence of ceramides AP and NP in stratum 
corneum of ROC, as well as the higher content of oleate of the expense of linoleate in 
ω–hydroxyceramides are not typical for rat skin (Wertz et al. 1984; Hansen and Jensen 
1985). In addition, the thermal lipid phase transitions of ROC were not identical to 
either human or rat skin (Al-Saidan et al. 1998). Therefore, the fact that ROC is 
reconstructed from rat keratinocytes cannot account for its observed differences from 
human skin. 
   Skin models may never fully mimic the identical functional properties of normal skin. 
A more crucial issue is how successful they are in predicting the behaviour of human 
skin e.g. in terms of permeation and irritation. Based on the results of the experimental 
section of this thesis, ROC can be considered as a potential alternative for native skin in 
pharmaceutical testing. It was shown to be a very good predictor of in vivo chemical 
skin irritation. Based on the present and previous results (Suhonen et al. 2003) the ROC 
can be stated to be a good permeation model as well, and produce a barrier function 
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very similar to that of human skin. Thus, it can be used, with some limitations, in 
evaluating the effect of permeation enhancers. The hydrophilic permeation pathway of 
ROC was more easily altered with tested enhancers than that of human skin, a factor 
which should be taken into account to avoid overestimation of results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 65
7 CONCLUSIONS 
 
   In the present study, an epidermal skin model, ROC, was evaluated and compared to 
the native human skin as a tool for testing pharmaceuticals and chemicals. The 
following conclusions are drawn: 
 
1. The main lipids of the SC were present in similar, but not identical, proportions in 
the ROC model as in human skin. There were some subtle differences in the general 
composition, molecular species, and amounts of covalently bound ceramides. 
 
2. Thermal behaviour of the ROC differed from that in the human skin indicating some 
structural differences in the lamellar lipid arrangement and a lower amount of 
covalently bound ceramides. 
 
3. A method for skin irritation testing using multiple-sampling and three biomarkers 
with different irritation responses was introduced. The validity of the ROC model as 
a predictor of the skin irritation by chemicals was demonstrated by using a set of 
compounds. Finally, improved predictive capacity compared to commercial skin cell 
models was demonstrated. 
 
4. The similar permeability coefficients of the lipophilic model drug, corticosterone, in 
the  enhancer treated membranes is evidence of a similar lipoidal permeation route 
as present in the SC. On the contrary, the higher permeability of the hydrophilic 
solute, sucrose, in the ROC model probably reflects a greater number of polar 
pathways in the ROC than in the HEM. The ROC model was also more sensitive to 
the less potent permeation enhancers than human skin. 
 
5. A similar circuit model was obtained for the ROC and human skin by impedance 
measurements. Both membranes had very high average transmembrane resistance, 
but the resistances in the ROC model was higher than that analysed in human skin. 
The permeation enhancers decreased the resistance of both membranes to a similar 
extent. In contrast, microemulsions decreased the resistance of HEM more 
extensively than the resistance of ROC. 
 
6. The novel microemulsions improved the permeation of estradiol extensively mainly 
due to their high solubilization power. The increased solubilization was explained 
by the solubility of estradiol in the individual microemulsion components rather 
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than any specific microemulsion structure as such. Microemulsions increased the 
permeability of estradiol in the ROC more than in the HEM. 
 
7. Overall, the ROC model displays significant structural similarities with human skin, 
but some differences in the barrier integrity were also observed. ROC seems to be 
the best in vitro model for the assessment of chemical irritation, but it is more 
sensitive than human skin to the effects of the permeation enhancers. Modulation of 
the culture conditions, such as addition of essential fatty acids on medium, may 
further improve the permeability barrier of ROC. 
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